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 Matrix metalloproteinases (MMPs) are classically associated with late stage metastases, 
though previous work by our lab and others have expanded the role of MMPs to all stages of 
tumor development.  Using a genetic model of intestinal tumorigenesis, the Min (multiple 
intestinal neoplasia) mouse, we previously demonstrated a role for MMPs, in particular MMP-7, 
in the development of intestinal adenomas.    To further explore the role of proteinases in the 
development of intestinal neoplasia, I created a novel microarray to examine more than 500 
proteases for differential expression in intestinal tumors.  Relative microarray analysis found that 
MMPs-10, -13, and -14 have the highest fold change in expression in tumor compared to normal 
samples, while absolute microarray analysis indicated that MMPs-9, -12, -15 and -19 are present 
in tumor samples but not normal intestine.  As a result of this screen, I generated Min mice 
genetically deficient for various proteinases that were differentially detected in Min adenomas 
(MMP-2, -9, -12, and -19).  Genetic ablation of MMP-2, -12, or -19 did not affect tumor number 
or size, however, MMP-9 deficient Min mice developed 25% fewer tumors than littermate 
controls.  Further, in the context of intestinal tumors, the major cellular source of MMP-9 is 
neutrophils thus suggesting a pro-tumorigenic role of inflammation in early tumorigenesis.  
Additionally, our screen detected several mast cell produced proteinases in tumor tissue that 
were absent from normal intestine.  To examine the effect of mast cell proteinases in 
tumorigenesis, I generated mast cell-deficient Min mice.  Surprisingly, these mice developed 
50% more tumors than mast cell Min mice, thus indicating that mast cells function in an anti-
tumorigenic role early during intestinal tumorigenesis.  Thus, these studies demonstrate that 
proteinases and infiltrating inflammatory cells function in both pro- and anti-tumorigenic roles 
during early intestinal tumor development. 
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CHAPTER I 
 
INTRODUCTION 
 
Colorectal Cancer 
General Characteristics, Staging, Pathology, and Genetics 
Colorectal malignancies are the fourth most common type and the second most 
common cause of cancer related deaths in the United States after cancers of the lung and 
bronchus (American Cancer Society, 2007a).  The disease occurs with equal frequency in 
both men and women. In 2004 there were more than 150,000 new cases and 
approximately 50,000 deaths due to colorectal cancer, and similar numbers are predicted 
for 2007 (American Cancer Society, 2007a).  Approximately 50% of the Western 
population is predicted to develop colorectal tumors by 70 years of age with 10% of these 
cases progressing to malignancy (Fahy and Bold, 1998).  Worldwide there are predicted 
to be more than 600,000 deaths due to colorectal cancer and more than 1,100,000 new 
cases diagnosed in 2007 (American Cancer Society, 2007b).  A variety of risk factors that 
predispose a person’s susceptibility to developing colorectal cancers have been identified 
including family history, inflammatory bowel disease (IBD) , the presence of 
adenomatous polyps and diet (Jacobs et al., 2007).   
The two most commonly used staging systems used to describe the progression of 
colorectal cancer are known as the Dukes’ and AJCC/TNM systems (Benson, 2007).  The 
Astler-Coller modification of Duke’s classification system groups colorectal cancers into 
four stages based upon the depth of invasion and metastasis to local lymph nodes and 
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distant organs (Astler and Coller, 1954).  These stages are Dukes’ A, which is defined as 
invasion into the underlying submucosa or muscularis propria but confinement to the 
bowel wall.  Stage B designates tumors that have invaded deeper, through the serosa, but 
not spread to local lymph nodes.  Dukes’ stages C1 and C2 identify tumors that have 
metastasized to lymph nodes, and are differentiated in that stage C1 tumors, like stage A 
are confined to the bowel wall, while C2 tumors have spread through the serosa.  Tumors 
that have spread to distant organs are designated as Dukes’ stage D (Astler and Coller, 
1954).   
In contrast, the American Joint Committee on Cancer (AJCC) and Union 
International Contre le Cancer (UICC) advocate a classification scheme known as TNM6 
(International Union against Cancer. et al., 2002).  In the TNM6 system scores are 
calculated based upon three variables:  the depth of invasion of the primary Tumor 
(scored 0-4), the number of lymph Nodes involved (scored 0-3), and the presence or 
absence of distant Metastasis (scored 0-1).  Based upon the individual T, N and M scores, 
tumors are then grouped into stages identified by the roman numerals I-IV, with stage IV 
being the most advanced stage (Table 1) (International Union against Cancer. et al., 
2002).   
Patient survival strongly correlates with stage, with decreasing survival correlated 
with increasing stage (Benson, 2007).  Patients diagnosed with Dukes’ A (Stage I) 
colorectal cancer have a 5 year survival of greater than 90%; however, survival drops to 
5% as the disease progresses and involves distant organ metastasis (Fry et al., 1989).  A 
second important variable that correlates with survival rate is the degree of differentiation 
of the tumor.  Tumors are classified as either well, moderately, or poorly differentiated 
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based upon histological criteria.  The majority of colorectal cancers are “moderately 
differentiated”, and cancers that are graded as “poorly differentiated” are significantly  
 
Table 1:  Comparison of Dukes’ Staging versus TNM6 grading schemes for 
colorecteal cancer.  Astler-Coller modification of Dukes’ stages (far left) is compared to 
the newer AJCC-TNM6 system, which measures the depth of invasion in the tumor (T), 
the number of positive lymph nodes (N), and presence or absence of distant metastases 
(M). 
 
 
more likely to be associated with metastasis than moderately or well-differentiated 
tumors (Fry et al., 1989). Colorectal cancers directly invade the bladder, prostate, vagina, 
uterus, ureters, perineural muscle, pelvic bones, and sacral plexus (Willett et al., 1999).   
Metastatic spread to distant organs most commonly involves the liver, which can be 
detected in 10-30% of patients at time of diagnosis (Gatta et al., 2000).  Less commonly, 
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metastases are found in the lungs, vertebrae, brain, and bone marrow (Kanthan et al., 
1999). 
Rather than one single disease, colorectal cancer includes several tumors of 
several different cellular origins.  Most colorectal tumors are of epithelial origin, which 
includes adenocarcinoma, mucinous adenocarcinoma, signet-ring adenocarcinoma, 
squamous cell carcinoma, and adenosquamous carcinoma subtypes.  However, several 
other tumor varieties can develop in the colon and rectum of non-epithelial origin 
including carcinoid tumors (neuroendocrine cells), lipomas (adipocytes), lymphomas 
(lymphoid cells), and leiomyosarcomas (smooth muscle) (Brunicardi et al., 2005).  
Adenocarcinoma of the colon, by definition a tumor of the glandular epithelium, is the 
most common variety of colorectal cancer, and accounts for 95% of all colorectal 
malignancies (Ponz de Leon and Di Gregorio, 2001).   
The progression from normal colonic epithelium to invasive cancer involves 
several discreet morphological and genetic modifications.  The earliest lesion identified 
in the development of colorectal tumors is the presence of aberrant crypt foci (ACF).  
ACF are small clusters of abnormal crypts that can exhibit a variety of histopathologic 
features typical of tumors including enlarged, crowded nuclei; stratification of epithelial 
cells; depletion of mucin; and varying degrees of dysplasia (Di Gregorio et al., 1997) that 
can be used to further refine ACF into three groups- dysplastic, non-dysplastic, and 
mixed (Cheng and Lai, 2003).   
Adenomatous polyps, the smallest detectable lesion by routine colonoscopy, are 
defined as well demarcated, circumscribed lumps of epithelial dysplasia, and are the most 
common precursor lesion detected in the gastrointestinal tract (Haber, 2002).  Polyps are 
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extremely common in the Western population, and have been reported in as much as 50% 
of individuals over 50 years of age (Ponz de Leon and Di Gregorio, 2001).  Two general 
morphological categories of polyps exist:  pedunculated, that is adenomas that possess a 
stalk; and sessile, which are flat adenomas that rise above the surface.  Very small lesions 
(<1 cm) are occasionally referred to as “diminutive”, though this designation is 
uncommon (Weston and Campbell, 1995).  Polyps can be further subdivided into three 
major histological categories (villous, tubular, and tubulovillous) based upon their tissue 
architecture.  However, distinguishing a tumor as one type is somewhat ambiguous as the 
spectrum of tumor morphology is more of a gradient than three discreet points (Morson 
and Day, 2003).   
Several genetic changes occur during the progression from normal intestinal 
mucosa to invasive colorectal cancer including mutations to both oncogenes such as K-
ras, and β-catenin (Bos et al., 1987; Morin et al., 1997); and tumor suppressor genes 
including APC (adenomatous polyposis coli), MCC (mutated in colorectal cancer), DCC 
(deleted in colorectal cancer), and p53 (Figure 1) (Fearon and Vogelstein, 1990; Groden 
et al., 1991; Hollstein et al., 1991; Kinzler et al., 1991).  While there are likely numerous 
pathways that result in the development of colorectal cancer, a large majority (70-85%) 
of tumors develop via the “traditional pathway”, also known as the chromosomal 
instability (CIN) pathway (Worthley et al., 2007).  The traditional pathway involves a 
mutation or loss of APC, a mutation of K-ras, a loss of chromosome 18q (DCC), and 
finally deletion of chromosome 17p, which contains the tumor suppressor gene p53 
(Grady, 2004).  This pathway was generated by genetic profiling of both spontaneous and 
familial colorectal tumors at a variety of stages and compiling the results into a sequence 
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that reconciled the genetic and morphologic changes that occur during the development 
of colorectal cancer (Fearon and Vogelstein, 1990).   
 
 
  
Figure 1:  Genetic alterations that occur in the development of colorectal neoplasia.  
Mutations in the tumor suppressor APC or β-catenin are the initiating event in the 
development of colorectal cancer, and are carried in the germline of patients with the 
hereditary cancer syndrome FAP.  HNPCC, another hereditary cancer syndrome, 
involves mutations in the mismatch repair genes MSH-2 and MLH-1.  (Adapted from 
Kinzler and Vogelstein, 1996.) 
 
 
Spontaneous mutations in APC occur in nearly 70% of sporadic colorectal 
adenomatous polyps (Powell et al., 1992), and germline mutations in APC are the 
causative agent of the hereditary condition familial adenomatous polyposis (FAP) 
(Groden et al., 1991; Kinzler et al., 1991; Nishisho et al., 1991).  Patients with FAP 
develop hundreds to thousands of adenomatous polyps which invariably progress to 
colorectal cancer (Rustgi, 2007).  APC is a large 15 exon gene with several functional 
domains and mutations often result in a truncated protein missing the carboxy terminus 
(Rustgi, 2007).    APC has been shown be involved in a number of cellular processes 
including cell cycle regulation, migration, microtubule assembly, cell adhesion, apoptosis 
and cell fate determination via protein-protein interactions (Rustgi, 2007). 
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The most widely associated role for APC is as a master regulator of the Wnt 
pathway.  The carboxy terminal region of APC along with axin and glycogen synthase 
kinase-3 (GSK3), is crucial for phosphorylation and ultimately degradation of β-catenin 
(Korinek et al., 1997; Morin et al., 1997; Su et al., 1993).  In the absence of functional 
APC, β-catenin accumulates within the cytoplasm and eventually the nucleus where it 
promotes the transcription of Wnt pathway target genes through an interaction with a 
family of DNA binding proteins known as T-cell factor (Tcf) or lymphoid enhancing 
factor (Lef) (Behrens et al., 1996; Huber et al., 1996; Korinek et al., 1997).  Tcf target 
genes shown to be activated by β-catenin include protooncogenes such as c-myc (He et 
al., 1998) and WISP-1 (Xu et al., 2000), matrix metalloproteinases (Crawford et al., 
1999), and other genes known to contribute to tumor formation (Mann et al., 1999).  
Further, tumors that lack mutations in APC frequently have mutations in β-catenin, thus 
underscoring the importance of this pathway in the development of colorectal cancer. 
In summary, the development of colorectal polyps is a frequently occurring 
disease that affects 50% of the population over 70 years of age.  Fortunately, because of 
advances in early detection, many of these cases are detected and treated by routine 
colonoscopy before they progress to malignant lesions.  However, our understanding of 
the cellular changes that occur during tumorigenesis and disease progression is still quite 
poor.  In my work, I have sought to understand molecular events occurring in the tumor 
microenvironment of early stage tumors with the goal of identifying protective and pro-
tumorigenic proteinases in particular. 
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The Min Mouse as a Model Organism of Intestinal Tumorigenesis 
The Min (multiple intestinal neoplasia) mouse is a commonly used model for 
studying the development and treatment of colorectal cancer.  Generated as part of a 
forward genetic screen using ethynitrosurea mutagenesis, these mice were identified after 
exhibiting severe adult-onset anemia that was the result of the development of dozens of 
tumors throughout both the small and large bowel (Moser et al., 1990).  The mutation is 
heritable in an autosomal dominant manner, and subsequently, a single nonsense 
mutation (TÆA transversion at base pair 2549) was found in the murine orthologue of 
the human APC gene (Su et al., 1992).  This mutation results in a premature STOP codon 
at position 850, and as with human tumors, a truncated form of APC missing the carboxy 
terminus is produced (Su et al., 1992).  Homozygosity for the Min allele is embryonic 
lethal due to a defect very early in embryogenesis (Tam and Loebel, 2007).  Mice 
heterozygous for this allele develop numerous benign tumors through the intestinal tract, 
and females are predisposed to develop spontaneous mammary tumors.  Further 
characterization of these tumors revealed that multiple epithelial lineages were involved, 
suggesting that lesions likely arise from initiated mutipotent stem cells (Moser et al., 
1992). 
Mice heterozygous for the Min allele develop many symptoms that resemble the 
human familial FAP condition; however, there are significant differences as well.  While 
FAP tumors tend to be distributed throughout the colon, tumors in Min mice are much 
more commonly found in the small intestine, though colonic polyps do occur (Shoemaker 
et al., 1997a).  Tumors range in size from 0.5-8mm in diameter and like human tumors 
are heterogeneous and can morphologically be either pedunculated or sessile (Moser et 
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al., 1990).  Tumors develop from individual cells that have lost the second allele of APC, 
can be detected in animals as early as four weeks old (Yamada et al., 2002), and are 
frequently aneuploid (Rao et al., 2005).    A key limitation to the Min model is that 
tumors that do form are almost always benign, rarely progressing to become locally 
invasive, and virtually never metastasize (Shoemaker et al., 1997a).  Other APC mutant 
mice have been developed with varying tumorigenic profiles.  Most notable are mice with 
mutations at codons 716 (APCΔ716) and 1638 (APCΔ1638N).  In the case of 
APCΔ1638N, these mice have been reported to develop liver metastases (Kucherlapati et 
al., 2001), however, the life span of APCΔ1638N mutants is significantly longer than Min 
animals, and tumors are not detectable until 25 weeks of age (Kucherlapati et al., 2001).  
Moreover, the number of tumors that develop in each of these models is significantly 
fewer than in the Min mouse. 
A number of genetic factors have been shown modulate tumor development in the 
Min system.  The genetic background of the animal has been shown to tremendously 
influence tumor multiplicity and progression.  To date, there have been 7 genetic loci 
identified as “modifier of min” with strain specific tumor-resistant and sensitive alleles 
(Kwong et al., 2007).  The best characterized modifier locus is Mom1.  Mom1 was 
initially described as a dominant acting allele that conferred resistance to tumor formation 
in the Min system, and was found in AKR/J, MA/MyJ and CAST/J strains, but not in 
C57Bl/6 (Dietrich et al., 1993).  The allele mapped to a 4 cM region of chromosome 4, 
and was eventually identified as a secretory phospholipase, Pla2g2a (Cormier et al., 
1997).  Other modifier loci have been identified that both encode proteins, like Mom1, 
and are in non-coding regions, like Mom7.  Further, many of these loci are highly 
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polymorphic with at least five variant alleles known to exist (Haines et al., 2005; Kwong 
et al., 2007). 
Aside from the well established utility of the Min model in identifying the role of 
genetic modifiers of colorectal carcinogenesis, the model is commonly used to evaluate 
the efficacy of chemopreventative pharmacologic agents.  An excellent example of this is 
the protective role of NSAIDs (non-steroidal anti-inflammatory drugs) in tumorigenesis.  
COX-2 (cyclooxygenase-2), an inducible enzyme that mediates the production of 
prostaglandins, is frequently over-expressed in a variety of human tumors.  COX-2 
produced prostaglandins have been shown to both stimulate proliferation and confer 
apoptosis resistance to tumor cells.  Treatment of Min mice with NSAIDs that inhibit 
COX-2 activity dramatically inhibited tumor formation (Boolbol et al., 1996) and paved 
the way for human clinical trials which had similar results (Rostom et al., 2007). 
A second example of the utility of pharmacologic agents in the Min system is in 
the case of MMPs (matrix metalloproteinases).  MMP-7, normally produced by Paneth 
cells in the intestine, is frequently localized to tumor cells in colorectal lesions 
(McDonnell et al., 1991; Wilson and Matrisian, 1996).  Min mice with MMP-7 
genetically ablated develop ~60% fewer tumors than do littermate controls, implicating 
MMP-7 as pro-tumorigenic mediator of tumorigenesis (Wilson et al., 1997). 
Pharmacological inhibitors of MMPs, known as MMPIs (MMP Inhibitors), were also 
tested in the Min model.  MMPIs with broad spectrum activity that includes MMP-7 
inhibition resulted in a 48-70% inhibition of tumor formation (Goss et al., 1998; 
Wagenaar-Miller et al., 2003), indicating that the results of genetic modification can be 
recapitulated chemically in the Min model. 
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Despite some key differences, the molecular and pathologic parallels to human 
disease make the Min model an excellent tool for studying the development and treatment 
of early-stage colorectal tumorigenesis.  Furthermore, genetic and pharmacologic studies 
in this model system have emphasized the importance of proteolytic enzymes, in 
particular MMP-7, in the development of intestinal neoplasms, thus making the MMPs an 
attractive target for further study.   
 
 
MMPs and Cancer 
The Matrix Metalloproteinase Family 
The matrix metalloproteinases (MMPs), a subfamily of extracellular zinc-
dependant proteinases belonging to the metzincin subclan, MA(M), involved in numerous 
biological processes (Rawlings et al., 1998).  The MMPs are Collectively, MMPs are able 
to degrade all structural components of the extra-cellular matrix (ECM) (Nagase et al., 
2006), though a number of non-ECM bioactive substrates for MMPs have been 
discovered (Sternlicht and Werb, 2001).  While the majority of MMP activity is 
extracellular, recent studies have indicated that in certain conditions MMP-1, -2 and -11 
may act on intracellular proteins (Kwan et al., 2004; Limb et al., 2005; Luo et al., 2002).  
To date, 25 vertebrate, 23 human, and 22 murine MMPs have been identified (Sternlicht 
and Werb, 2001).  Multiple structural motif similarities exist between family members 
including a conserved zinc binding motif (HEXXHXXGXXH) and  a “Met turn” (usually 
ALMYP) both within the catalytic domain, and a “cysteine switch” motif (PRCGXPD) in 
the pro domain (Sternlicht and Werb, 2001). 
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Individual MMPs are referred to by a sequential numeric nomenclature system 
reserved for vertebrate MMPs, though many have common names that reflect substrates, 
expression, or cellular localization.  Classically, human MMPs can be categorized into 6 
groups based upon substrate preference and domain architecture: the matrilysins, the 
collagenases, the gelatinases, the stromelysins, the membrane-type MMPs, and “others”- 
MMPs that do not fit well into any of the other groups (Figure 2) (Nagase et al., 2006).   
The minimal domain structure that distinguishes MMPs consists of three domains 
required for secretion (pre domain), enzyme latency (pro domain), and catalysis (catalytic 
domain) (Nagase and Woessner, 1999).  The matrilysins are the only MMPs to have the 
minimal domain structure.  With one exception, MMP-23, all other vertebrate MMPs 
contain a hemopexin/vitronectin-like domain that is juxtaposed to the catalytic domain 
through a short linker region.  Rather than a hemopexin domain, MMP-23 contains a 
unique C-terminal cystein-array/immunoglobulin like domain.   
MMP-7 (matrilysin, MEROPS M10.008) and MMP-26 (matrilysin-2, 
endometase, MEROPS M10.029) are the two members of the matrilysins.  While humans 
have both members of this group, rodents lack MMP-26, which to date has only been 
detected in primate genomes (Huxley-Jones et al., 2007).  MMP-7 acts on a wide variety 
of ECM substrates including non-fibrillar collagens, gelatins, fibronectins, and 
proteoglycans (Quantin et al., 1989; Sellers and Woessner, 1980; Woessner and Taplin, 
1988).  Additionally, several non-ECM substrates for MMP-7 have been identified 
including pro-α-defensin, Fas-ligand, pro-tumor necrosis factor, and E cadherin (Nagase 
et al., 2006).  MMP-26 has the ability to proteolyze a number of ECM molecules as well, 
though, unlike most MMPs, is largely intracellulary stored (Nagase et al., 2006).   
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Figure 2:  Domain architecture of the MMP family.  MMP family members can be 
classified into five broad domains based upon substrate specificity and domain 
architecture.  Abbreviations are as follows:  Fn repeats (fibronectin repeats), H (hinge 
region), O (O-glycosylated domain), F (furin cleavage site), TM I (transmembrane 
domain Type I), GPI (GPI anchor), C Array (‘Cysteine array’), Ig Like (Ig-like domain). 
 
 
 
 
The collagenases include MMP-1 (interstitial collagenase, MEROPS M10.001), 
MMP-8 (neutrophil collagenase, MEROPS M10.002), MMP-13 (collagenase-3, 
MEROPS M10.013), and MMP-18 (Xenopus collagenase, MEROPS M10.018, not 
present in humans or mice).  Like the vast majority of MMPs, collagenases contain a 
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heompexin domain, that when present, influences enzyme activation, substrate binding, 
membrane activation and has been shown to have some catalytic activity (Sternlicht and 
Werb, 2001).  Collagenases are best known for their ability to degrade native, fibrillar 
collagen, though, like with all MMPs, non-matrix substrates have been found as well 
(Nagase et al., 2006).  Mice and rats have two copies of the gene for MMP-1, designated 
as mcola and mcolb, though these genes are only rarely expressed, and MMP-13 acts as 
the major collagenase in these animals (Balbin et al., 2001). 
The gelatinase group consists of two enzymes- MMP-2 (gelatinase A, 72kDa 
gelatinase, MEROPS M10.003) and MMP-9 (gelatinase B, 92kDa gelatinase, MEROPS 
M10.004).  Gelatinases contain three fibronectin type II repeats within the catalytic 
domain that bind to and aid in the degradation of gelatin (Murphy et al., 1994).  In 
addition to denatured collagen, the gelatinases have been shown to degrade type IV, V 
and XI collagen, laminin, and aggrecan; and, MMP-2, but not MMP-9, has been 
demonstrated to have some collagenolytic activity, but the in vivo relevance of this is not 
yet known (Nagase et al., 2006; Patterson et al., 2001). 
There are three members of the stromelysin subgroup: MMP-3 (stromelysin-1, 
transin, MEROPS M10.005), MMP-10 (stromelysin-2, transin-2, MEROPS M10.006) 
and MMP-11 (stromelysin-3, MEROPS M10.007).  The stromelysins and collagenases 
have similar domain architectures, but the stromelysins are unable to cleave insterstitial 
collagen (Nagase et al., 2006).  MMP-3 and -10 are highly homologous proteins with 
similar structure and substrate specificity, but differ in their tissue expression.  
Stromelysins-1 and -2 degrade a wide variety of ECM substrates including laminin, 
fibronectin, entactin, collagen IV, and proteoglycans.  However, MMP-11 is only 
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distantly related to the other stromelysins, and has been demonstrated to have only weak 
activity towards ECM components, but has been shown to readily cleave serpins (a class 
of serine protease inhibitors) (Murphy et al., 1993; Pei et al., 1994).    Evolutionary 
analysis of nucleotide sequence suggests that MMP-11 is more closely related to the 
membrane type MMPs than to the other stromelysins, though it is still classified as a 
stromelysin for historical purposes (Massova et al., 1998). 
  The membrane-type MMPs can be subdivided into two groups.  There are four 
type I transmembrane MMPs: MMP-14 (MT1-MMP, MEROPS M10.014), MMP-15 
(MT2-MMP, MEROPS M10.015), MMP-16 (MT3-MMP, MEROPS M10.016), and 
MMP-24 (MT5-MMP, MEROPS M10.023), and two glycosylphosphatidylinositol-
anchored proteins: MMP-17 (MT4-MMP, MEROPS M10.017), and MMP-25 (MT6-
MMP, MEROPS M10.024).  Like MMP-11, all members of the membrane-type group 
contain a furin recognition motif at the C-terminus of the propeptide (Nagase et al., 
2006).  MT1-MMP has been shown to have collagenolytic activity towards collagens I, II 
and III (Ohuchi et al., 1997) and mutant mice lacking this enzyme display skeletal defects 
suggesting a critical role for MT1-MMP in osteogenesis (Holmbeck et al., 1999).  A 
second important role for MT1-MMP is in cell surface activation of pro-MMP-2 (Sato et 
al., 1994), a capability probably also existing in MT2 and MT3-MMPs (Page-McCaw et 
al., 2007).  Additionally, MMP-23 (cysteine array MMP, MEROPS M10.022), while not 
classically classified as a membrane-type, is proposed to be a type II membrane protein 
having a transmembrane domain at the N-terminus of the propeptide (Pei et al., 2000). 
The remaining MMPs that do not fit well into any of the other categories, and are 
grouped together as “other MMPs”.  Three of the MMPs in this group (MMP-12, MMP-
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20, and MMP-27) have structural and genomic homology to the stromelysins, but are not 
classified as such.  MMP-12 (macrophage metalloelastase, MEROPS M10.009) has been 
shown to degrade elastin, fibronectin, proteoglycans and is primarily expressed by 
macrophages, but is also detected in chondrocytes and osteoclasts (Hou et al., 2004; 
Kerkela et al., 2001).  MMP-19 (RASI, MEROPS M10.021), was first detected in the 
activated lymphocytes and plasma from patients with rheumatoid arthritis, and has a very 
wide expression pattern including most organs and proliferating keratinocytes (Sadowski 
et al., 2003).  MMP-20 (enamelysin, MEROPS M10.019) has an extremely restricted 
expression pattern and is found in newly formed tooth enamel and during periodontal 
disease (Ryu et al., 1999).  MMP-21 (Xenopus MMP, XMMP, MEROPS M10.026), is a 
poorly characterized MMP with a wide expression pattern, and is commonly expressed 
by basal and squamous cell carcinomas (Ahokas et al., 2003).  MMP-27 (chicken MMP, 
CMMP, MEROPS M10.027) was originally detected in chicken embryo fibroblasts 
where it was given the designation MMP-22.  However, in mammals it is only known 
from genomic sequences and to date has not been characterized (Yang and Kurkinen, 
1998).  The last member of the “other” group, MMP-28 (epilysin, MEROPS M10.030), is 
thought to function in wound repair and is detected in a wide variety of tissues including 
cartilage, heart, lung, placenta, testis, and the gastrointestinal tract (Saarialho-Kere et al., 
2002).  Like MMPs-11 and -17, MMPs-21, -23 and -28 contain furin recognition 
sequences adjacent to the catalytic domain suggesting that they are likely to be 
intracellularly activated and secreted as activate enzymes (Nagase et al., 2006).    
Lastly, a specialized class of protein inhibitors known as the tissue inhibitors of 
metalloproteinases (TIMPs) are frequently associated with the MMPs.   There are 4 
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TIMP family members, and TIMPs reversibly inhibit MMP activity and demonstrate 
some inhibitory selectivity towards particular MMP family members.  In addition, TIMPs 
have also been shown to also mediate activation of pro-MMPs by acting as a scaffolding 
partner and bringing the pro-MMP is close juxtaposition to an activating proteinase 
(Sternlicht and Werb, 2001). 
 
Regulation of MMP Activity 
The expression and activation of MMPs is tightly regulated at multiple levels to 
ensure that active MMPs are present only in appropriate conditions.  This strict control 
affects every stage of the MMP’s lifecycle including modulators of transcription, 
translation, secretion, activation, and catalytic activity of mature enzymes.  
Transcriptional control of MMPs can be up- or downregulated by factors including 
several growth factors (TGFβ, EGF), ECM proteins, phorbol esters (12-O-tetradecanoyl-
phorbol-13-acetate [TPA]), cell stress, and changes in cell shape (Parks and Mecham, 
1998).  Many of these stimuli function by inducing the expression or activity of the proto-
oncogenes c-fos and c-jun, which bind AP-1 sites within the promoter region of several 
MMPs (Sternlicht and Werb, 2001).  However, while some stimuli coordinately regulate 
some MMP genes, other stimuli can have differential effects.  In humans, transforming 
growth factor-β (TGFβ) signaling increases transcription of MMP-13, but downregulates 
expression of MMPs-1 and -3 (Uria et al., 1998).  Additionally, the same stimulus may 
have different effects on expression depending on the cellular target.  Cultured human 
keratinocytes express MMP-10 when treated with TPA, but fibroblasts react to the same 
stimulus by expressing MMP-3 (Windsor et al., 1993).  Thus, MMP transcription is 
17 
 
dependent upon the context of not only appropriate stimulus, but of cellular origin as 
well.   
While atypical for MMPs, mechanisms do exist that affect transcribed MMP 
sequences prior to translation and effectively modulate activity and amount of mature 
protein.  One way that MMP activity is modulated is by the production of splice variants.  
There are several splice variants of MMP-16, normally a cell surface associated protein, 
and one splice variant results in the production of a soluble and proteolytically active 
isomer (Matsumoto et al., 1997).  MMPs also may be regulated by modulating the 
stability of mature mRNA, prior to translation.  Stabilizing mRNA results in more 
proteins produced per mRNA molecule, thus effectively increasing the concentration of 
the target gene.  For example, phorbol esters and epidermal growth factor (EGF) have 
been shown to stabilize transcripts of MMP-1 and MMP-3 (Delany et al., 1995).   
Conversely, TGFβ has been shown to destabilize MMP-13 transcripts, resulting in fewer 
molecules of MMP-13 made per transcript (Delany et al., 1995).  
Freshly synthesized MMPs contain two domains that are absent in active 
enzymes, a pre- and a pro- domain.  Prior to secretion of pro-MMPs, a hydrophobic 
stretch of amino acids known as the ‘pre’ domain is removed.  This pre-domain is 
important for targeting MMPs for extracellular secretion.  While most MMPs are secreted 
constitutively once they are translated, instances exist of where pro-MMPs are stored in 
secretory granules until the cell receives an appropriate stimulus.  Circulating neutrophils, 
a class of leukocytes, synthesize and store MMP-8 and MMP-9 in tertiary granules, 
which are only released following neutrophil activation by specific pro-inflammatory 
mediators (Hasty et al., 1990).  A second example of this is MMP-12, which is produced 
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and then stored by macrophages until an appropriate stimulus (protein kinase C activation 
as a result of PAR-1 stimulation) leads to secretion (Raza et al., 2000).  Furthermore, 
evidence exists that MMP-26 may also be stored intracellularly, but the molecular 
mechanisms behind this are unknown (Marchenko et al., 2004). 
Most MMPs are synthesized and secreted as inactive zymogens (proMMPs) that 
must first be activated to become enzymatically capable of acting on substrates.  A 
mechanism commonly referred to as “stepwise activation” is used to cleave the pro 
domain and produce an active MMP.   Stepwise activation refers to a two-step 
mechanism whereby a proteinase susceptible bait region is removed from the pro region 
by non-specific proteinases resulting in a conformational change.  This conformational 
change allows other MMPs, or in some circumstances the MMP intermediate itself, to 
completely remove the remainder of the propeptide, and produce a mature, active protein 
(Nagase et al., 1990).  MMP-2, however, is an interesting exception to this mechanism, 
and is activated at the cell surface through a multistep pathway that involves MMP-14 (or 
MMP-15) and TIMP-2.  In this tri-molecular mechanism, activated MMP-14 on the cell 
surface binds to and is inhibited by free TIMP-2.  The C-terminal domain of the bound 
TIMP-2 acts as a receptor for the hemopexin domain of proMMP-2, which is then 
cleaved by a second molecule of MMP-14, and activated by a second molecule of MMP-
2 (Deryugina et al., 2001).  This system has a secondary control in that low levels of 
TIMP-2 favor activation of MMP-2, while high levels of TIMP-2 saturate free MMP-14 
and thus prevent MMP-2 activation. 
Finally, once active, MMPs are sensitive to inhibition by protein inhibitors- the 
TIMPs.  To date, four TIMP members have been identified: TIMP-1, TIMP-2, TIMP-3, 
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and TIMP-4 (Sternlicht and Werb, 2001).  TIMP family members share a 37-51% 
sequence homology, and as a group reversibly inhibit all MMP family members in a 1:1 
stoichiometry (Clendeninn and Appelt, 2001).   TIMPs contain 12 highly conserved 
cysteine residues that form six intrachain disulfide bridges to produce a six-loop, two-
domain structure (Williamson et al., 1990).  Additionally, there are non-specific 
proteinase inhibitors such as the serum constituent α2-macroglobulin.  Like MMPs, the 
expression pattern of TIMPs varies considerably between tissues, and individual TIMPs 
differ in their ability to bind and inhibit MMPs (Woessner and Nagase, 2000).  Thus, 
multiple control mechanisms exist that allow for tight control of MMP activity at several 
levels (Figure 3).  These mechanisms frequently overlap; resulting in distinct expression 
patterns and generating feedback loops that result in tightly regulated MMP expression, 
activation, and activity. 
 
MMPs in Tumorigenesis and Cancer Progression 
Cancer is the result of a progressive series of genetic and physiologic events that 
disrupt the normal tissue homeostasis.  In 2000, Hanahan and Weinberg described 
“Hallmarks of Cancer”, six events that are essential in the transformation from normal 
cells to a malignant neoplasm.  These events are: (i) immortalization, (ii) resistance to 
apoptosis, (iii) self sufficiency with respect to growth signals, (iv) insensitivity to anti-
proliferative signals, (v) sustained angiogenesis, and (vi) the ability to invade local and 
distant tissues (Hanahan and Weinberg, 2000).  By virtue of a degrading a wide variety of 
ECM substrates and localizing to the invasive edge, MMPs have been historically 
associated with only the latest of these hallmarks - local invasion and metastasis.   
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 Figure 3:  Regulation of MMPs occurs at multiple levels.  MMPs activity is tightly 
regulated at the RNA level through control of (1) transcription, (2) post-transcriptional 
splicing, and (3) RNA stabilization.  At the protein level MMP activity is modulated by 
(4) storage in vesicles until an appropriate signal mediates controlled release, (5) 
activation of latent pro-enzymes to a catalytically active form, and (6) inhibition by a 
class of endogenous proteins known as TIMPs. 
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However, several lines of experimental evidence have demonstrated roles for MMPs at 
all stages of tumor development in both pro- and anti- tumorigenic roles (Lopez-Otin and 
Matrisian, 2007; Martin and Matrisian, 2007; Noel et al., 2008).Aberrant MMP activity 
has been shown to mediate the earliest stages of tumorigenesis.  MMP-3, a stromally 
expressed MMP, is commonly over-expressed in breast tumors.  Exposure of a normal 
mammary epithelial cell line, Scp2, to MMP-3 causes cells to undergo epithelial to 
mesenchymal transition (EMT), presumably through the cleavage of E-cadherin, and a 
loss of cell-cell adhesions (Radisky et al., 2005).  Further, MMP-3 treated cells express a 
splice variant of Rac1, which causes intracellular concentration reactive oxygen species 
(ROS) to increase.   High intracellular ROS concentrations directly cause oxidative 
damage of DNA and subsequently genomic instability, as well as the promotion of EMT 
by stimulating the expression of the transcription factor Snail (Radisky et al., 2005; 
Sternlicht et al., 1999). 
MMP overxpression has been shown to produce tumors that are refactory to pro-
apoptotic stimuli, a process that is thought to work through Darwinian selection for 
resistant clonal populations.  Fas ligand (FasL) is a type II membrane protein expressed 
by several inflammatory cell lineages and upon binding to its receptor, Fas, rapidly 
induces a signal cascade that ultimately results in target cell apoptosis.  Using a mouse 
model of prostate involution, a process dependent upon FasL-Fas interactions, mice that 
lack MMP-7 have a 67% decrease in apoptotic index, when compared to wild type 
controls (Powell et al., 1999).  MMP-7 has been shown to generate a soluble form of 
FasL that is functionally competent, and rapidly induces apoptosis of cells in culture upon 
acute exposure.  However, chronic exposure to this soluble form selects for a population 
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of cells that are refractory to Fas mediated apoptosis (Fingleton et al., 2001; Vargo-
Gogola et al., 2002).   
MMPs are capable of stimulating tumor cell proliferation in a number of ways.  
Perlecan and decorin, two components of the ECM, bind and sequester fibroblast growth 
factor (FGF) and TGF-β, respectively, both of which can be liberated by MMP activity, 
and result in cellular proliferation (Imai et al., 1997; Whitelock et al., 1996).  Similarly, 
MMPs are capable of degrading inhibitory binding proteins, resulting in the release of 
active growth factors.  Insulin-like growth factor binding proteins (IGF-BPs) bind to and 
sequester active IGFs, limiting their bioavailability.  By direct proteolytic cleavage, 
MMP-7 degrades IGF-BP3, and releases active IGF-II which promotes cellular 
proliferation (Miyamoto et al., 2007).  MMPs activity directly can convert inactive 
growth factors to an active form, as seen by MMP-2 and MMP-9 processing of inactive 
TGF-β to an active form (Yu and Stamenkovic, 2000).  Thus, by degrading inhibitory 
binding proteins, or by directly liberating or activating latent growth factors, MMPs have 
been shown to modulate proliferation of tumor cells.   
Angiogenesis, the process by which tumors become vascularized, is both 
positively and negatively regulated by MMPs.  Vascular endothelial growth factor 
(VEGF), a potent stimulator of angiogenesis, exists in an inactive complexed state bound 
to connective tissue growth factor (CTGF).  This complex is attacked by MMP-14, CTGF 
is degraded, releasing active VEGF and stimulating angiogenesis(Hashimoto et al., 
2002).  Further, VEGF is cleaved by MMPs-3 and MMP-9 to generate a truncated protein 
incapable of binding heparin sulfates, and thus promoting an irregular pattern of 
neovascularization (Lee et al., 2005).  Additionally, since VEGF binds strongly to matrix 
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proteins due to heparin binding domains, degradation of ECM by MMPs is thought to be 
another mechanism by which MMPs can increase levels of bioactive VEGF (Bergers et 
al., 2000).  Conversely, MMP activity can inhibit angiogenesis.  MMPs--3, -12, -19, and -
25 cleave cell-surface urokinase-type plasminogen activator receptor (uPAR), resulting in 
less cellular urokinase plasminogen activator (uPA) binding, and consequently, 
diminished formation of angiogenic structures (Andolfo et al., 2002; Koolwijk et al., 
2001).  A number of studies have shown that anti-angiogenic peptides such as angiostatin 
or tumstatin can be generated by MMP cleavage of plasmin or collagen IV, respectively.  
In this regard, MMP-12 mediated generation of angiostatin is considered to be highly 
relevant to its apparent anti-tumor role (Acuff et al., 2006; Cornelius et al., 1998; 
Houghton et al., 2006).  Similarly, MMP-9 appears to suppress tumor growth in some 
models through generating of angiostatin or tumstatin (Chen et al., 2005; Hamano et al., 
2003). 
Several studies have recently detailed other apparently protective, anti-
tumorigenic roles for MMPs.  Mice lacking MMP-8, an enzyme predominantly expressed 
by neutrophils, develop significantly more papillomas than littermate controls when 
treated with DMBA+TPA, a common chemical carcinogenesis model of skin 
tumorigenesis.  This effect was rescued by bone-marrow transplantation, demonstrating 
that neutrophil-derived MMP-8 is sufficient to restore the protective effect of this MMP 
(Balbin et al., 2003).  Similarly, mice deficient for MMP-3 develop tumors sooner than 
littermate controls, and this increased growth rate was coupled with an elevated rate of 
proliferation, though apoptosis was unaffected (McCawley et al., 2004).  In both of these 
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studies, MMP-mediated alteration of chemokines was suggested as the mechanism 
behind the effects seen. 
In conclusion, in recent years the role of MMPs in tumor development has expanded 
dramatically.  Historically, MMPs have been viewed as pro-tumorigenic, and in 
particular, associated with pro-metastatic spread, although current evidence demonstrates 
that MMPs are key players during all stages of tumor development.  Several MMPs are 
differentially over-expressed in human colon cancer.  To date, MMPs-1, -2, -3, -7, -8, -9, 
-10, -11, -12, -14, -21, and -25 have been found to be more abundant in colon tumors 
compared to normal colonic tissue.  Conversely, MMP-19 and -28, while normally 
present in colon tissue, are less abundant in colonic neoplasms, however, the 
consequence of the dysregulation of these MMPs is unclear (Ahokas et al., 2002; Bister 
et al., 2004; Sun et al., 2007; Wagenaar-Miller et al., 2004).  Because of the expanded 
role of MMPs to include all stages of tumor development, and the protective, anti-
tumorigenic role observed for several MMPs, I aimed to generate a comprehensive 
profile of MMPs expressed in a mouse model of colorectal tumor development.  
Furthermore, genetic ablation of several MMPs in the Min system allowed me to 
investigate functions of specific pro- and anti-tumorigenic MMPs that can be used to 
develop more specific MMPIs.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Mice Breeding and Genotyping 
Preparation of Genomic DNA 
 Genomic DNA for genotype analysis was prepared from the distal tip of the tail 
by incubating a 3mm section of tail in 100μl of a lysis buffer composed of 25 mM NaOH, 
0.2 mM EDTA.  After incubation in the lysis buffer for 25 minutes at 95° C, 100μl of 40 
mM Tris-HCl solution was added to neutralize the alkali, and the preparation was briefly 
mixed by vortexing. 
 
Min Mice 
 Min mice (C57Bl/6J-APCMin/+) were purchased from the Jackson Laboratory (Bar 
Harbor, ME) to establish a breeding colony with wild-type C57Bl/6J mice from the same 
source.  All mice were maintained on a high-fat 5015 diet (LabDiet, Purina, St. Louis, 
MO) which has been shown to enhance tumorigenesis in the Min model system (van 
Kranen et al., 1998).  Pups were weaned at 3 weeks of age and genotyped by PCR 
analysis.  A 340 base pair product was amplified using the primers 5’- TTC TGA GAA 
AGA CAG AAG TTA-3’ and 5’-TTC CAC TTT GGC ATA AGG C-3’.  PCR reactions 
contained 50 pmol each primer (Invitrogen), 1μl NaOH isolated genomic DNA, and 
HotstarTaq master mix (Qiagen, Valencia, CA) consisting of Taq polymerase, reaction 
buffer, and dNTPs.  Reactions were performed on a RoboCycler Gradient 96 (Strategene, 
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La Jolla, CA) using the following program:  15 min at 94° C (1 cycle); 30 sec at 94° C, 1 
min at 55° C, 1 min at 72° C (35 cycles); 2 min at 72° C (1 cycle).  The product from this 
PCR reaction was run out on a 1.5% agarose 1X TBE gel containing 0.001% (v/v) 
ethidium bromide and visualized under UV light. 
 
Generation of MMP-2-/- Min Mice 
 Min mice lacking MMP-2 were generated by crossing female mice deficient for 
MMP-2 (Itoh et al., 1997) with male mice carrying the Min allele.  Resulting female 
offspring heterozygous for MMP-2, were crossed with male mice heterozygous for 
MMP-2 and carrying the Min mutation.  Four week old mice were genotyped for MMP-2 
by PCR analysis using genomic DNA isolated from the tail as previously described and 
the following primers:  MMP-2 KO FW:  5’-TAG AAT TCC TGC AGC CCG-3’, MMP-
2 KO RV: 5’-CAA ACT ACA ACC AGC TGC TC-3’ (knockout product 243bp); MMP-
2 WT FW: 5’-CAA CGA TGG AGG CAC GAG TG-3’, MMP-2 WT RV: 5’-GCC GGG 
GAA CTT GAT CAT GG-3’ (wild type product 535bp).  PCR reactions contained 50 
pmol each primer (Invitrogen), 1μl NaOH isolated genomic DNA, and HotstarTaq master 
mix (Qiagen, Valencia, CA) consisting of Taq polymerase, reaction buffer, and dNTPs.  
Reactions were performed on a RoboCycler Gradient 96 (Strategene, La Jolla, CA) using 
the following program:  15 min at 94° C (1 cycle); 1 min at 94° C, 45 sec at 52° C, 30 sec 
at 72° C (33 cycles); 7 min at 72° C (1 cycle).  Resulting products were run out on a 1.5% 
separated on a 1.5% agarose gel by electrophoresis and visualized with ethidium 
bromide. 
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Generation of MMP-2-/-;MMP-7-/-Min Mice 
 Min mice deficient for both MMP-2 and MMP-7 were generated by crossing 
female mice deficient for MMP-2 with male mice deficient for MMP-7.  The resulting 
female offspring, heterozygous for both MMPs (MMP-2-/+;MMP-7-/+), were crossed back 
to a male MMP-7 deficient animal generating animals heterozygous for MMP-2, but 
lacking MMP-7 (MMP-2-/+;MMP-7-/-).  Non-littermate F2 animals were then crossed to 
generate mice lacking both MMP-2 and MMP-7 (MMP-2-/-;MMP-7-/-).  Double knock 
out female animals were crossed with a male mouse heterozygous for the Min allele, but 
wild type for both MMP loci to generate a single male MMP-2-/+;MMP-7-/+;APCMin/+ 
founder, from which four discrete lines were selectively generated- mice lacking MMP-2 
(MMP-2-/-;APCMin/+), MMP-7 (MMP-7-/-;APCMin/+), double deficient (MMP2-/-;MMP-7-/-
;APCMin/+) and wild type controls (APCMin/+) (Figure 4). 
 
Generation of MMP-9-/- Min Mice 
 MMP-9 deficient Min mice were generated by crossing female mice deficient for 
MMP-9 (Vu et al., 1998) with male mice carrying the Min allele.  Resulting female 
MMP-9 heterozygous pups, were crossed with male pups carrying the Min allele and 
heterozygous for MMP-9.  Four week old mice were genotyped for MMP-9 by PCR 
analysis using genomic DNA isolated from the tail as previously described and the 
following primers:  MMP-9 KO FW:  5’-CTC AGA AGA ACT CGT CAA GA-3’, 
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 Figure 4:  Summary of the breeding strategy used to generate MMP-2; MMP-7 
double deficient Min mice.  To minimize genetic variation between lines, a single 
APCMin/+; MMP-7-/+; MMP-2-/+ male founder was used to selectively generate four 
separate mouse lineages to examine the effect of ablating MMP-7 and MMP-2 in the Min 
model.   
 
 
MMP-9 KO RV: 5’-GGA TTG CAC GCA GGT TCT CC-3’; MMP-9 WT FW: 5’-GCA 
TAC TTG TAC CGC TAT GG-3’, MMP-9 WT RV: 5’-TAA CCG GAG GTG CAA 
ACT GG-3’ were used to generate a 600bp product indicative of the knockout allele, and 
a 300bp product indicative of the wild type allele.  PCR reactions contained 50 pmol each 
primer (Invitrogen), 1μl NaOH isolated genomic DNA, and HotstarTaq master mix 
(Qiagen, Valencia, CA) consisting of Taq polymerase, reaction buffer, and dNTPs.  
Reactions were performed on a RoboCycler Gradient 96 (Strategene, La Jolla, CA) using 
the following program:  15 min at 94° C (1 cycle); 1 min at 94° C, 1 min at 58° C, 1 min 
at 72° C (35 cycles); 5 min at 72° C (1 cycle).  Resulting products were run out on a 1.5% 
agarose gel and visualized using ethidium bromide. 
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 Generation of MMP-12-/- Min Mice 
MMP-12 deficient Min mice were generated by crossing female mice deficient 
for MMP-12 (Shipley et al., 1996) with male mice carrying the Min allele.  Resulting 
female progeny heterozygous for the MMP-12 allele, were crossed with male siblings 
carrying the Min allele and heterozygous for MMP-12.  Four week old mice were 
genotyped for MMP-12 by PCR analysis using genomic DNA isolated from the tail as 
previously described and the following primers:  MMP-12 KO FW:  5’-GAC CAC CAA 
GCG AAA CAT-3’, MMP-12 KO RV: 5’- CAA GAA GGC GAT AGA AGG -3’; 
MMP-12 WT FW: 5’-GCA TAC TTG TAC CGC TAT GG-3’, MMP-12 WT RV: 5’-
TAA CCG GAG GTG CAA ACT GG-3’ were used to generate a 150bp product 
indicative of the knockout allele, and a 230bp product indicative of the wild type allele.  
PCR reactions contained 50 pmol each primer (Invitrogen), 1μl NaOH isolated genomic 
DNA, and HotstarTaq master mix (Qiagen, Valencia, CA) consisting of Taq polymerase, 
reaction buffer, and dNTPs.  Reactions were performed on a RoboCycler Gradient 96 
(Strategene, La Jolla, CA) using the following program:  15 min at 94° C (1 cycle); 30 
sec at 94° C, 30 sec at 55° C, 20 sec at 72° C (35 cycles); 5 min at 72° C (1 cycle).  
Resulting products were run out on a 2% agarose gel and visualized with ethidium 
bromide. 
 
Generation of MMP-19-/- Min Mice 
MMP-19 deficient Min mice were generated by crossing female mice deficient 
for MMP-19 (Pendas et al., 2004) with male Min mice.  Resulting female MMP-19 
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heterozygous pups were crossed with male pups heterozygous for MMP-19 and carrying 
the Min allele.  Four week old mice were genotyped for MMP-19 by PCR analysis using 
genomic DNA isolated from the tail as previously described and the following primers:  
MMP-19 KO FW:  5’-TCT TGA TTC CCA CTT TGT GGT TC-3’, MMP-19 KO RV: 
5’-GTC CGG CTC ATC CTC GAC TAT TT-3’; MMP-19 WT FW: 5’-TTT GGT AGG 
GCA GGA GTT AAT GG-3’, MMP-19 WT RV: 5’-GGT AGG TTG GAG GGC AAG 
AGG AA-3’ were used to generate a 1500bp product indicative of the knockout allele, 
and a 300bp product indicative of the wild type allele.  PCR reactions contained 50 pmol 
each primer (Invitrogen), 1μl NaOH isolated genomic DNA, and HotstarTaq master mix 
(Qiagen, Valencia, CA) consisting of Taq polymerase, reaction buffer, and dNTPs.  
Reactions were performed on a RoboCycler Gradient 96 (Strategene, La Jolla, CA) using 
the following program:  15 min at 95° C (1 cycle); 30 sec at 95° C, 30 sec at 55° C, 30 
sec at 72° C (38 cycles); 10 min at 72° C (1 cycle).  Resulting products were run out on a 
1.5% agarose gel and visualized with ethidium bromide. 
 
Generation of c-kitW-sh/W-sh Min Mice 
 Male and female Min (C57Bl/6J-APCMin/+), Sash (C57Bl/6J-c-kitW-sh/W-sh) and 
wild type littermates (C57Bl/6J) were bred in our laboratory from breeder mice obtained 
from The Jackson Laboratory (Bar Harbor, ME).  Min-Sash (C57Bl/6/J APCmin/+;c-kitW-
sh/W-sh) mice were generated by crossing a male Min mouse with female Sash (C57Bl/6/J - 
c-kitW-sh/W-sh) mice.  The resulting mice, heterozygous for the W-sh allele, were crossed to 
each other, carrying the Min allele along the paternal lineage.  Mice were genotyped for 
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the Min allele by PCR and for the Sash mutation based upon coat color (Grimbaldeston et 
al., 2005). 
 
Tissue Collection, Processing and Tumor Measurements 
Tissue Collection and Tumor Measurements 
 Intestines were excised from freshly sacrificed animals, flushed with PBS, filled 
with 10% phosphate buffered formalin and fixed overnight at 4ºC.  The following day, 
intestines were rinsed and immersed in 70% ethanol for long term storage.  Tumor 
incidence and location were recorded with the aid of a dissecting microscope by two 
counters, one of which is blinded to the genotype of the animals.  Tumor diameter at the 
widest point was measured to the nearest 100μm using digital calipers and a dissecting 
microscope. 
 Tumors designated for histological analysis were excised with minimal surrounding 
uninvolved tissue and paraffin embedded on end using a histoprocessor (Tissue-Tek 
Vacuum Infiltration Processor) according to the manufacturer’s instructions.  5 μm thick 
sections were cut and mounted on Superfrost Plus glass slides (Fisher Scientific) for 
histological or immunohistochemical analyses. 
 
RNA Isolation, Microarray and Real-Time PCR Analysis 
RNA Isolation 
Pools of small intestinal adenomas were harvested from the ilea of six 15-week 
old Min mice.  To prevent contamination of control tissue with microscopic tumors, 
normal ileal tissue was harvested from non-Min littermates for use as control tissue.  
Samples obtained from individual mice were processed and analyzed independently. 
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Tissues were placed into RNAlater solution (Qiagen, Valencia, CA) and stored 
overnight at 4ºC.  The following day, total RNA was isolated from and purified using an 
RNeasy mini kit (Qiagen).  Briefly, 5 adenomas were pooled such that they had a total 
mass of 150mg.  For control samples, 150mg of normal ilea with Peyer’s patches 
removed was used.  Tissue was rinsed in DEPC treated PBS to remove residual 
RNAlater, then immersed in 2ml Trizol reagent (Invitrogen, Carlsbad, CA) and 
homogenized using a rotor/stator homogenizer.  Trizol prepared RNA was further 
purified using a Qiagen RNeasy Mini kit with on column RNase-free DNase I digestion 
(Qiagen). 
RNA concentration and integrity was measured by the Vanderbilt Microarray 
Shared Resource (VMSR) using a NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies, Wilmington, DE) and Agilent 2100 Bioanalyzer (Agilent Technologies, 
Santa Clara, CA), respectively.  Samples showing a RNA integrity number (RIN) of less 
than 7.0 were excluded from further analysis. 
 
cDNA Microarray Construction 
 A custom cDNA microarray containing probes capable of identifying species 
specific human and murine MMPs and TIMPs was constructed by cloning divergent 
regions of orthologous genes.  Briefly, divergent regions were identified by aligning 
orthologues and highly homologous genes as previously identified using the 
CLUSTALW multi-sequence alignment tool (Massova et al., 1998; Thompson et al., 
1994).  Divergent regions of low homology were visually identified from CLUSTAL W 
alignments and targeted for probe construction.  To ensure that divergent regions were 
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specific for the gene of interest, nucleotide sequences were submitted to the BLAST 
(Basic Local Alignment Search Tool) search algorithm and compared against both the 
human and murine genomic sequences, and considered unique if no other transcripts 
were detected with an e score of less than 1x10-30 (Altschul et al., 1990). 
 Once identified, targeted sequences were cloned by obtaining EST (Expressed 
Sequence Tag) clones (Research Genetics, Huntsville, AL) of the region of interest to be 
used as a template for PCR amplification.  However, in several instances, EST coverage 
of unique regions was poor and genomic DNA or RT-PCR generated cDNA products 
were used as templates (Table 2).  Additionally, several orthologous MMPs exhibited 
extremely high homology between human and murine sequences such that creating 
probes capable of differentiating between sequences was not possible.  Thus, gene 
profiling of MMPs-16, -19, -24, -25, -27 and -28 are shared common probes for human 
and murine and cannot differentiate between species.    
Probes were generated by PCR amplification of targeted regions from publicly 
available EST clones.  PCR reactions were performed by using EST positive bacteria as a 
template and a re-annealing temperature gradient of 47-58°C on a Robocycler Gradient 
96 thermocycler (Stratagene).  Specifically, 5μl of bacteria containing the EST of interest 
was used as a template for a 50ul PCR reaction containing 20pmol each primer using a 
Promega 2X PCR Taq kit (Promega).  Eight identical reactions were setup for each 
probe, reactions were first heated to 95ºC for 5 minutes to lyse the EST containing 
bacteria, reactions were then amplified for 35 cycles: 30 seconds melt at 95ºC, 1 minute 
reannealing across a 47-58ºC gradient, and 1 minute extension at 72ºC.  Resulting  
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Table 2:  Summarization of primers and templates used for generation of cDNA 
probes.   .  Abbreviations  H: Human, M: Mouse, EST: Expressed Sequence Tag, 
cDNA: coding DNA. 
 
 
Gene Species Source Forward Primer Reverse Primer 
MMP-1 H Subclone 5’-TTT CTT TCA TGG AAC 
AAG AC-3’ 
5’-TTT TGT ACC CAC CAT TTG 
TG-3’ 
 M Genomic 5’-AAA AAC GTG AAT GGC 
AAG GA-3’ 
5’-TGT GTT TTG GTC CAA CGA 
GG-3’ 
MMP-8 H EST 5’-GTT TAT AAT CCT GTA 
GGT CAG-3’ 
5’-AAA CTG CTG AGA ATT ACC 
TA-3’ 
MMP-11 M EST 5’-TGG GGG AAC TGG AGT 
GTC CTT GCT G-3’ 
5’-AGC AGT GCT GCG AAA 
AGG GCT TCA G-3’ 
MMP-12 M cDNA 5’-TGA AGG GTG CTT GCT 
GGT TTT-3’ 
5’-TTA CAG ATA AAC CAG TTG 
GCC TCT G-3’ 
MMP-14 H cDNA 5’-CGC AGC CTC CTT GCT 
TCT CT-3’ 
5’-GGG GCT GGA CAG ACA 
CAA AG-3’ 
 M EST 5’-GGC TGC TCT CAC CCG 
TCC TG-3’ 
5’-TTG CCT TCA AGT GCA GAG 
CC-3’ 
MMP-15 H EST 5’-TGT GGT TCT GAG ATG 
GCT CCC AGG G-3’ 
5’-ACC AGG GGG GCC AGA 
CAG TCT CC-3’ 
 M EST 5’-ATC AGG TAG CAC ACC 
GCA GC-3’ 
5’-TGT GTG TGG CTA GGA GGG 
CA-3’ 
MMP-16 H Genomic 5’-CCC AGT AAA ATT TCA 
GGA TT-3’ 
5’-GAA GTT CAA TTG TGG GTT 
TT-3’ 
MMP-17 H EST 5’-TGT TGG TCT GGA ACG 
CGT CAC AGG G-3’ 
5’-GCT GGG CAG GCT CAG GTG 
GCA AG-3’ 
 M EST 5’-GGA TCC CCA GTA CTC 
AGC AGG ACT TG-3’ 
5’-GCC CTC GAG AAC TCT CTT 
ACT TGT GAA AC-3’ 
MMP-19 H/M EST 5’-CGA TAT TCC CAG GCC 
CTC ATG-3’ 
5’-AGA CAC TCG GAA CAA 
GGG GC-3’ 
MMP-20 H cDNA   
 M cDNA 5’-GTC GTG TGT CAG AGA 
CAC TC-3’ 
5’-CAC ACA CAT GAG TGC ACA 
TA-3’ 
MMP-23 H EST 5’-CAG CCC TGA GCC CCA 
CAG CA-3’ 
5’-AGC GCA GCA ACG TCT CCC 
TG-3’ 
 M EST 5’-GGC ACG AGG CCT ACG 
TCG CG-3’ 
5’-ACA TTT CCC TGA GCT GCA 
TT-3’ 
MMP-24 H/M EST 5’-GCC AAG CTT ACT CCC 
CCT CAT TAA TGT TG-3’ 
5’-GCC CTC GAG AAA AGG 
TAG TTT GGG TTA GG-3’  
MMP-25 H/M EST 5’-GCG CTT CCC CAA GAA 
CAG CA-3’ 
5’-TGT TCG GTC TGG ATG GCT 
CC-3’ 
MMP-26 H cDNA 5’-GCC AAG CTT CAG ACA 
TCA AGG TTT CTT TC-3’ 
5’-GCC TCG AGA TTA TGG AGC 
TCT GAT TCC C-3’ 
MMP-27 H/M EST 5’-GCC AAG CTT AGA CAT 
GTC TTC TCC AAG TC-3’ 
5’-GCC CTC GAG ATC ATA AGA 
GTT TAA GCT TG-3’ 
MMP-28 H/M EST 5’-CGC TGA CAT CCG GCT 
CAC CTT CTT C-3’ 
5’-TGG GAG CTG GAC GGC CAC 
TGA G-3’ 
TIMP-1 M Subclone 5’-CTA AAA GGA TTC AAG 
GCT GT-3’ 
5’-AAA ACT CTT TGC TGA GCA 
GG-3’ 
TIMP-3 H EST 5’-CAG GAG ACA CTA CCC 
TTC CA-3’ 
5’-ATC TAA GAA GCC TCT ACC 
CC-3’ 
TIMP-4 H EST 5’-TTT TTG GTT TCA TTC 
CTG CC-3’ 
5’-AAG AAG TGC CAA GTG 
GAC AG-3’ 
 M EST 5’-GTC CTT TGA CCA TCA 
CCA CCT G-3’ 
5’-TTG GGA GAC AGG GAA 
GAG GG-3’ 
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products were gel purified using low melting point agarose (SeaKem) and ligated into 
pCR2.1-TOPO using a Topoisomerase I mediated ligation according to manufacturer’s 
directions (TOPO-TA cloning kit, Invitrogen).  DNA was prepared using a Qiagen 
MaxiPrep column, and 20μg of purified plasmid DNA was provided to the Vanderbilt 
DNA Sequencing Core for sequencing to ensure that the constructed probe was free of 
PCR artifacts.  Probe sequences were then realigned with their target sequences using 
CLUSTALW for annotation purposes.  Positive clones were supplied to the Vanderbilt 
Microarray Shared Resource (VMSR), amplified using M13 primer sites that flank the 
probe sequence and spotted onto glass microarray slides. 
 
MMP-1 
 Human:  A 314-base pair fragment corresponding to bases 1382-1695 of human 
MMP-1 (NM_002421) was subcloned by PCR into pCR2.1-TOPO-TOPO (Invitrogen) 
from a plasmid containing a sub-clone of human MMP-1 using the following primers: 
FW: 5’-TTT CTT TCA TGG AAC AAG AC-3’ and RV:5’-TTT TGT ACC CAC CAT 
TTG TG-3’. 
 Murine:  A 205-base pair fragment corresponding to bases 128-332 of murine 
MMP-1b (mcolb, NM_032007), but common to both mcola and mcolb was cloned into 
pCR2.1-TOPO using murine genomic DNA as a template.  The primers used for this 
reaction were FW: 5’-AAA AAC GTG AAT GGC AAG GA-3’ and RV:5’-TGT GTT 
TTG GTC CAA CGA GG-3’. 
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MMP-2 
 Human:  An 884-base pair fragment corresponding to bases 1201-2084 of human 
MMP-2 (NM_004530.1) was previously generated by inserting an PvuII-BamHI 
fragment of human MMP-2 into pBluescript KS II+ (Rodgers et al., 1994).  
 Murine:  A 1089-base pair fragment corresponding to bases 890-1987 of murine 
MMP-2 (NM_008610.1) was created by inserting an RT-PCR product murine post 
partum uterus origin into pGEM3Z.  RT-PCR was performed using primers FW:5’-GGT 
GGC AAT GCT GAT GGA CA-3’ and RV:5’-TTG GTT CTC CAG CTT CAG GT-3’ 
(Reponen et al., 1992). 
 
MMP-3 
 Human:  A 555-base pair fragment corresponding to bases 1227-1781 of human 
MMP-3 (NM_002422.2) was previously generated by inserting a ClaI-AccI fragment of 
full length human MMP-3 into pGEM7Z  (McDonnell et al., 1991). 
 Murine:  A 480-base pair fragment corresponding to bases 904-1383 of murine 
MMP-3 (NM_010809.1) was previously generated by inserting a KpnI-XhoII fragment 
of murine MMP-3 into pGEM4 (Witty et al., 1995). 
 
MMP-7 
 Human:  A 818-base pair fragment corresponding to bases 20-837 of human 
MMP-7 (NM_002423.2) was previously generated by inserting a XhoI-XbaI fragment of 
full length human MMP-7 into pGEM7Z  (McDonnell et al., 1991). 
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 Murine:  A 479-base pair fragment corresponding to bases 406-884 of murine 
MMP-7 (NM_010810.1) was previously generated by RACE PCR from RNA of post 
partum uterus origin as previously described (Witty et al., 1995). 
 
MMP-8 
 Human:  A 501-base pair fragment corresponding to bases 1532-2032 of human 
MMP-8 (NM_002424.1) was previously generated by PCR amplification (Heppner et al., 
1996). 
Murine:  A 260-base pair fragment corresponding to bases 177-436 of murine 
MMP-8 (NM_008611.2) was cloned into pCR2.1-TOPO using an EST (AI265065) as a 
template.  The primers used for this reaction were FW: 5’- GTT TAT AAT CCT GTA 
GGT CAG-3’ and RV:5’- AAA CTG CTG AGA ATT ACC TA-3’. 
 
MMP-9 
Human:  A 798-base pair fragment corresponding to bases 1537-2334 of human 
MMP-9 (NM_004994.1) was cloned by generating a EcoRV-HindIII fragment using a 
full length cDNA template (Heppner et al., 1996). 
Murine:  An 835-base pair fragment of murine MMP-9 (NM_013599.1) was 
previously cloned by isolating an EcoRV-NdeI fragment from full length murine MMP-9 
cDNA (Rudolph-Owens, unpublished). 
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MMP-10 
Human:  A 528-base pair fragment corresponding to bases 1047-1574 of human 
MMP-10 (NM_002425.1) was cloned by generating a EcoRV-NdeI fragment into 
pGEM5Z using a full length cDNA template  (McDonnell et al., 1991). 
Murine:  A707-base pair fragment corresponding to bases 632-1338 of murine 
MMP-10 (NM_019471) was created by restriction digest of full length murine MMP-10 
cDNA with PstI and SacI.  The resulting fragment was ligated into pGEM4 (Witty et al., 
1995). 
 
MMP-11 
 Human:  A 324-base pair fragment corresponding to bases 1819-2160 of human 
MMP-11 (NM_005940.2) was generated by PCR using an EST (BG104963) as a 
template and primers FW:5’- TGG GGG AAC TGG AGT GTC CTT GCT G-3’ and 
RV:5’- AGC AGT GCT GCG AAA AGG GCT TCA G-3’.  The resulting product was 
inserted into pCR2.1-TOPO. 
 Murine: A 1042-base pair fragment corresponding to bases 998-2039 of murine 
MMP-11 (NM_008606.1) was created by digesting a cDNA for full length murine MMP-
11 with restriction enzymes PvuII and PstI, and the resulting fragment was inserted into 
pGEM5Z (Rudolph-Owen et al., 1997). 
 
MMP-12 
 Human: A 424-base pair fragment corresponding to bases 1-423 of human MMP-
12 (NM_002426.1) was generated by digesting a cDNA for full length human MMP-12 
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with restriction enzymes HindIII and BamHI, and the resulting fragment was inserted 
into pGEM7Z (Curci et al., 1998). 
 Murine: A 242-base pair fragment corresponding to bases 1401-1642 of murine 
MMP-12 (NM_008605.1) was produced by PCR amplification using a full length cDNA 
for murine MMP-12, and primers FW:5’- TGA AGG GTG CTT GCT GGT TTT-3’ and 
RV:5’- TTA CAG ATA AAC CAG TTG GCC TCT G-3’.  The resulting amplicon was 
inserted into pCR2.1-TOPO. 
 
MMP-13 
 Human:  A 690-base pair fragment corresponding to bases 103-792 of human 
MMP-13 (NM_002427.2) was inserted into pGEM-T for use as a in situ hybridization 
probe (Vaalamo et al., 1997). 
 Murine:  An 838-base pair fragment corresponding to bases 1624-2461 of murine 
MMP-13 (NM_008607.1) was amplified by PCR and inserted into pGEM7Z (Rudolph-
Owen et al., 1997).   
 
MMP-14 
 Human:  A 180-base pair fragment corresponding to bases 2091-2270 of human 
MMP-14 (NM_004995.2) was cloned from a full length cDNA by PCR using the primers 
FW:5’-CGC AGC CTC CTT GCT TCT CT-3’ and RV:5’-TTG CCT TCA AGT GCA 
GAG CC-3’ and inserted into pCR2.1-TOPO. 
 Murine:  A 216-base pair fragment corresponding to bases 1999-2214 of murine 
MMP-14 (NM_008608.1) was cloned from an EST (accession BE332566) using the PCR 
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primers FW:5’-GGC TGC TCT CAC CCG TCC TG-3’ and RV:5’-TTG CCT TCA AGT 
GCA GAG CC-3’ and inserted into pCR2.1-TOPO. 
 
MMP-15 
 Human:  A 366-base pair fragment corresponding to bases 2097-2462 of human 
MMP-15 (NM_002428.1) was generated by PCR amplifying a corresponding region of 
an EST (BG327005) using the primers FW:5’-TGT GGT TCT GAG ATG GCT CCC 
AGG G-3’ and RV:5’-ACC AGG GGG GCC AGA CAG TCT CC-3’ and inserted into 
pCR2.1-TOPO. 
 Murine: A 105-base pair fragment corresponding to bases 2002-2106 of murine 
MMP-15 (NM_008609.1) was PCR amplified using an EST (BF537603) as a template 
and primers FW:5’-ATC AGG TAG CAC ACC GCA GC-3’ and RV:5’-TGT GTG TGG 
CTA GGA GGG CA-3’.  The resulting amplicon was ligated into pCR2.1-TOPO. 
 
MMP-16 
 Human and Murine:  The loci encoding human and murine MMP-16 (are highly 
homologous and EST coverage is poor.  Accordingly, a single probe to a highly 
conserved region common to both orthologues was constructed for this MMP.  Primers 
FW:5’-CCC AGT AAA ATT TCA GGA TT-3’ and RV:5’-GAA GTT CAA TTG TGG 
GTT TT-3’ were used to amplify a 234-base pair fragment using human genomic DNA 
(Promega) as a template.  The resulting product was inserted into pCR2.1-TOPO. 
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MMP-17 
 Human:  A 325-base pair fragment corresponding to bases 2076-2400 of human 
MMP-17 (NM_016155.2) was cloned from an EST (AI829838) using PCR primers 
FW:5’-TGT TGG TCT GGA ACG CGT CAC AGG G-3’ and RV:5’-GCT GGG CAG 
GCT CAG GTG GCA AG-3’ and inserted into pCR2.1-TOPO. 
 Murine:  A 372-base pair probe for murine MMP-17 (NM_011846.3) 
corresponding to bases 1897-2268 was constructed using an EST (BF471718) as a 
template for PCR amplification with the primers FW:5’-GGA TCC CCA GTA CTC 
AGC AGG ACT TG-3’ and RV:5’-GCC CTC GAG AAC TCT CTT ACT TGT GAA 
AC-3’.  The resulting amplicon was inserted into pCR2.1-TOPO. 
 
MMP-19 
 Human and Murine:  Human and murine MMP-19 exhibit a high degree of 
homology, and no ESTs specific for murine MMP-19 are commercially available.  
Because of this, a single probe was constructed that would recognize both human and 
murine MMP-19 transcripts.  To create this probe, a 312-base pair region of a human 
EST (AA481345) was cloned by PCR amplification.  Primers FW:5’-CGA TAT TCC 
CAG GCC CTC ATG-3’ and RV:5’-AGA CAC TCG GAA CAA GGG GC-3’ were used 
to generate an amplicon which was then inserted into pCR2.1-TOPO. 
 
MMP-20 
 Human:   A 512-base pair fragment corresponding to bases 926-1437 of human 
MMP-20 (NM_004771.2) was cloned from full length cDNA (J. Caterina) using PCR 
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primers FW:5’-TGA AAT CTA GTT CTT GGA TTG GTT G-3’ and RV:5’-TCT AAT 
GTG GAT TGA AAT TC-3’ and inserted into pCR2.1-TOPO. 
 Murine:  A 254-base pair fragment of murine MMP-20 (NM_013903.1) 
corresponding to bases 1539-1792 was cloned from a full length cDNA provided by C. 
Overall using primers FW:5’-GTC GTG TGT CAG AGA CAC TC-3’ and RV:5’- CAC 
ACA CAT GAG TGC ACA TA-3’ for PCR.  The resulting amplicon was inserted into 
pCR2.1-TOPO. 
 
MMP-21 
 Human and Mouse:  MMP-21 is a poorly characterized MMP with highly 
restricted expression currently only detected during narrow developmental windows and 
during certain malignancies (Ahokas et al., 2002).  Furthermore, searching for suitable 
EST clones to use as template for generating a probe for either human or murine MMP-
21 (NM_147191.1 and AY124569.1, respectively) revealed no suitable ESTs that are 
commercially available.  Thus, the decision was made to omit MMP-21 from the array. 
 
MMP-23 
 Human:  A 201-base pair probe corresponding to bases 11-211 of human MMP-
23A (AJ005256.1) was generated by PCR amplification using primers FW:5’- CAG CCC 
TGA GCC CCA CAG CA-3’ and RV:5’- AGC GCA GCA ACG TCT CCC TG-3’ and 
an EST (BI834812) as a template.  The resulting fragment was ligated into pCR2.1-
TOPO. 
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 Murine:  A 207-base pair fragment of murine MMP-23 (NM_011985.1) 
corresponding to bases 159-365 was cloned from an EST (BF549980.1) using PCR 
primers FW:5’- GGC ACG AGG CCT ACG TCG CG-3’ and RV:5’- ACA TTT CCC 
TGA GCT GCA TT-3’, the resulting aplicon was gel purified and ligated into pCR2.1-
TOPO. 
 
MMP-24 
 Human:  Because of a high degree of homology between human and murine 
MMP-24, a shared probe was generated. 
 Murine:  A 348-base pair fragment of murine MMP-24 (NM_10808.3) 
corresponding to bases 2854-3201 was cloned from an EST (AB021226) using PCR 
primers FW:5’- GCC AAG CTT ACT CCC CCT CAT TAA TGT TG-3’ and RV:5’- 
GCC CTC GAG AAA AGG TAG TTT GGG TTA GG-3’ and the resulting fragment was 
ligated into pPCR-Script (Stratagene). 
 
MMP-25 
 Human and Murine:  Murine MMP-25 currently only exists as a theoretical 
sequence based upon genomic sequencing, to date full length cDNA has not been 
published.  Further, human and murine MMP-25 (NM_022468.3 and NM_001033339.1, 
respectively) exhibit nearly 100% homology when aligned using CLUSTALW or 
FASTA.  Thus, a decision was made to generate a shared probe. 
 To do this, a 263-base pair fragment was cloned from a human EST 
(NM_022468.3) using the PCR primers FW:5’- GCG CTT CCC CAA GAA CAG CA-3’ 
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and RV:5’- TGT TCG GTC TGG ATG GCT CC-3’.  The cloned fragment was gel 
purified and inserted into pCR2.1-TOPO. 
 
MMP-26 
 Human:  A 238-base pair fragment of human MMP-26 (AF248646.1) 
corresponding to bases 449-686 was cloned from a full length cDNA provided by Q. A. 
Sang using the PCR primers FW:5’- GCC AAG CTT CAG ACA TCA AGG TTT CTT 
TC-3’ and RV:5’- GCC TCG AGA TTA TGG AGC TCT GAT TCC C-3’, and inserted 
into pCR2.1-TOPO. 
 Murine:  MMP-26 has only been detected in primate genomes to date, thus no 
probe was generated. 
 
MMP-27 
 Human and Murine:  As with MMP-25, murine MMP-27 only exists as a 
theoretical sequence based upon genomic sequencing, an human and murine MMP-27 
(NM_022122.1 and NM_001030289.1, respectively) exhibit nearly 100% homology 
when compared by CLUSTALW alignment.  Thus, a decision was made to generate a 
shared probe. 
 A 152-base pair probe corresponding to bases 1478-1629 of human MMP-27 was 
produced by PCR amplification using an EST (AI436025.1) as a template and FW:5’- 
GCC AAG CTT AGA CAT GTC TTC TCC AAG TC-3’ and RV:5’- GCC CTC GAG 
ATC ATA AGA GTT TAA GCT TG-3’ as primers.  The resulting amplicon was 
propogated by insertion into pCR2.1-TOPO. 
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MMP-28 
 Human and Murine:  Human and murine MMP-28 (NM_024302.2 and 
NM_080453.2, respectively) exhibit an extremely high degree of homology thus a single 
probe that recognized both sequences was generated.  A 356-base pair fragment of human 
MMP-28 corresponding to bases 809-1164 was generated by PCR amplification using an 
EST (BI914743) as a template and the primers FW:5’- CGC TGA CAT CCG GCT CAC 
CTT CTT C-3’ and RV:5’- TGG GAG CTG GAC GGC CAC TGA G-3’, the resulting 
product was gel purified and ligated into pCR2.1-TOPO.  
 
TIMP-1 
 Human:  A 650-base pair fragment of human TIMP-1 (NM_003254.1) 
corresponding to bases 68-717 was previously generated  
 Murine:  A 212-base pair fragment of murine TIMP-1 (NM_011593.1) 
corresponding to bases 211-422 was generated by PCR amplification using a previously 
described subclone as a template (Rudolph-Owen et al., 1997) and FW:5’- CTA AAA 
GGA TTC AAG GCT GT-3’ and RV:5’- AAA ACT CTT TGC TGA GCA GG-3’ as 
primers.  The resulting fragment was ligated into pCR2.1. 
 
TIMP-2 
 Human:  A 446-base pair fragment of human TIMP-2 (S48568.1) corresponding 
to bases 508-953 was previously generated and inserted into pGEM3Z by Ken Newell. 
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 Murine:  A 364-base pair fragment of murine TIMP-2 (M82858.1) corresponding 
to bases 294-657 was previously generated by digesting a full length cDNA with PstI and 
KpnI and ligating the resulting fragment into pGEM3Z (Rudolph-Owen et al., 1997). 
 
TIMP-3 
 Human:  A 294-base pair probe corresponding to bases 4031-4324 of human 
TIMP-3 (U14394.1) was produced by PCR amplification using an EST (BG621406) as a 
template and FW:5’- CAG GAG ACA CTA CCC TTC CA-3’ and RV:5’- ATC TAA 
GAA GCC TCT ACC CC-3’ as primers.  The resulting product was ligated into pCR2.1-
TOPO. 
 Murine:  A 318-base pair fragment of murine TIMP-3 (NM_011595.1) 
corresponding to bases 578-895 was previously generated by digesting full length TIMP-
3 cDNA with EcoRI and PstI, the resulting fragment was gel purified and ligated into 
pBlueScript KSII(+) (Rudolph-Owen et al., 1997). 
 
TIMP-4 
 Human:  A 331-base pair fragment of human TIMP-4 (NM_003256.1) 
corresponding to bases 843-1173 was generated by PCR amplification using an EST 
(AW293304) as a template and FW:5’- TTT TTG GTT TCA TTC CTG CC-3’ and 
RV:5’- AAG AAG TGC CAA GTG GAC AG-3’ as primers.  The aplicon produced by 
this reaction was gel purified and ligated into pCR2.1-TOPO. 
 Murine:  A196-base pair fragment corresponding to bases 735-930 of murine 
TIMP4 (AF282730.1) was generated by PCR amplification of an EST (AW047381) 
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using the primers FW:5’- GTC CTT TGA CCA TCA CCA CCT G-3’ and RV:5’- TTG 
GGA GAC AGG GAA GAG GG-3’, resulting in a fragment that was then ligated into 
pCR2.1-TOPO. 
 
Affymetrix Hu/Mu ProtIn Array Construction 
In conjuction with the Protease Consortium, a novel microarray capable of 
distinguishing between closely related homologous and orthologous protease transcripts 
was created on the Affymetrix platform.  The constructed array, known as the Hu/Mu 
ProtIn Array, or alternatively as Protease Chip (Affymetrix product “Protease520066F”), 
contains 972 custom probesets that cover all identified human and murine  proteinases, 
proteinase inhibitors, and interacting proteins (Schwartz et al., 2007). 
Initially, default Affymetrix probe sets were used for construction of the array, 
however, not all probes were species specific.  To fix this, probes set sequences provided 
by Affymetrix were compared to orthologous and highly homologous sequences by 
BLAST-N analysis with weighting for “short, nearly exact matches” (Altschul et al., 
1990).  Unique and highly homologous regions prone to cross talk were identified and 
probes were then redesigned and by Affymetrix to avoid homologous regions. 
Microarray analysis was performed using the Hu/Mu ProtIn array, product 
#Protease520066F (Affymetrix, Santa Clara, CA) (Schwartz et al., 2007).  cRNA 
synthesis, labeling, fragmentation and microarray hybridization, scanning, and analysis of 
differentially expressed transcripts was performed by the VMSR. 
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Real Time PCR Analysis 
Real-time PCR analysis of mast cell protease genes (mcpts) and MMPs was 
performed on RNA samples used for microarray analysis to further characterize mast cell 
protease expression.  cDNA was synthesized from 1μg total RNA using an iScript cDNA 
reverse transcriptase kit, following the manufacturer’s instructions (Bio-Rad, Hercules, 
CA).   The resulting cDNA products were diluted 1:5 using sterile distilled water prior to 
real-time PCR analysis.    Real-time PCR reactions were performed using IQ Real-Time 
Supermix with SYBR Green (Bio-Rad) on a Bio-Rad iQ5 thermocycler.  Reactions were 
run in triplicate for murine mcpt and MMP gene family members using previously 
described PCR primers (Martinez et al., 2005; Yamada et al., 2003) with a standard 2-
step amplification program. Fold change was determined by comparing the mean Ct 
levels between tumor and control samples, after adjusting for reference gene expression 
(GAPDH), significance was determined by using a two-sample t-test as previously 
described (Bowen et al., 2006). 
 
Histochemical and Immunohistochemical Analyses 
Chloroacetate Reaction (CAE) to Demonstrate Mast Cells 
Five-micron paraffin embedded, formalin-fixed sections were dewaxed and 
brought to water through graded alcohols.  To demonstrate mast cells in tumor and 
normal tissue the chloroacetate reaction (Leder, 1979) was performed using Fast Blue BB 
(Sigma, St. Louis, MO), counterstained using Alum-Kernechtrot (Humason, 1979) and 
mounted in permount (Sigma).  Positive cells were counted per unit area as measured by 
NIH ImageJ software. 
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Immunohistochemistry 
Five-micron paraffin embedded, formalin-fixed sections were dewaxed and 
brought to water through graded alcohols.  Sections were treated with 0.6% hydrogen 
peroxide in methanol to destroy endogenous peroxidase prior to antigen retrieval.  
Antigen retrieval was accomplished by heat denaturation by microwaving sections for 10 
minutes in a 10mM sodium citrate solution, except where noted.  Non-specific binding 
was inhibited by incubation in a blocking solution (10mM Tris-HCl pH7.4, 0.1M MgCl2, 
0.5% Tween20, 1% BSA, 5% Serum) for 1hr at room temperature.  Primary antibodies 
were diluted in blocking solution and applied at 4 C° overnight.  Appropriate IgG 
controls were used on adjacent sections to evaluate background staining.  Sections were 
washed with TBST (150mM NaCl, 10mM Tris, 0.05% Tween 20) and incubated with 
appropriate biotinylated secondary antibody for 1hr at room temperature.  Positive cells 
were visualized with an avidin-biotin peroxidase complex (Vectastain Avidin-Biotin 
Complex kit, Vector Laboratories, Burlingame, CA) and 3,3’-diaminobenzidine 
tetrahydrochloride substrate (Sigma).  Nuclei were counterstained with Mayer’s 
hematoxylin (Sigma), washed in TBS, dehydrated through alcohols, cleared in xylenes 
and mounted. 
 
Immunohistochemical Visualization of Proliferation and Apoptosis 
Proliferating cells were detected by immunohistochemical staining for phospho-
Histone H3 (Ser10) (Upstate, Lake Placid, NY).  Secions were prepared as described 
using heat denaturation.  Primary antibody was applied at a 1:250 dilution overnight at 4° 
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C overnight, and detected using a goat anti-rabbit secondary (Vector Laboratories, 
Burlingame, CA).  
Alternatively, in BrdU treated animals, proliferation was measured by staining for 
BrdU incorporation.  Briefly, mice were given a single injection of 75mg/kg BrdU in 
PBS one hour before sacrifice.  Incorporated BrdU was then detected with a monoclonal 
antibody (Accurate Chemical, Westbury, NY) using trypsin denaturation according to the 
manufacturer’s directions.  Monoclonal primary antibody was applied at a 1:400 dilution 
at 4° C overnight, and a (mouse immunoabsorbed) rabbit anti-rat secondary antibody was 
used at 1:500. 
Apoptotic nuclei were visualized by immunohistochemical staining of cleaved 
caspase-3(Asp175) (Cell Signaling Technology, Danvers, MA) using citrate antigen 
retrieval.  A 1:400 dilution of a  polyclonal primary antibody was applied overnight, and 
a 1:500 dilution of biotinylated goat anti-rabbit IgG was used for visualization using 
DAB as a substrate.  Alternatively, TUNEL staining according to manufacturer’s 
instructions (Millipore, Billerica, MA) on adjacent sections for comparison between 
methods. 
 
Immunohistochemical Demonstration of Leukocyte Populations 
Eosinophils were detected using a monoclonal rat antibody specific to murine 
major basic protein (MBP), kindly provided by James J. Lee, Ph.D. (Mayo Clinic 
Arizona, Scottsdale, AZ).   Antigen was retrieved using Dako antigen retrieval solution 
(Dako, Glostrup, Denmark) and 3-in-1 proteinase solution (Zymed, Carlsbad, CA).  
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Primary antibody was applied at 1:500 dilution overnight at 4° C, and a biotin conjugated 
rabbit anti-rat (mouse immunoabsorbed) was used to detect positive cells. 
Neutrophils were stained using a monoclonal anti-neutrophil antibody (AbD 
Serotec, Oxford, UK) at 1:100 dilution, and a rabbit anti-rat secondary antibody.  T cells 
were visualized using polyclonal antibodies recognizing CD3ε (Santa Cruz 
Biotechnology, Santa Cruz, CA) at 1:1500, and a rabbit anti-goat secondary (Vector 
Laboratories).  Macrophages were demonstrated by staining for F4/80 antigen using a 
monoclonal antibody and proteinase K antigen retrieval (AbD Serotec) at 1:100 dilution 
overnight at 4° C and a rabbit anti-rat secondary. 
 
MMP-9 and von Willebrand Factor Immunohistochemistry 
Paraffin embedded, formalin-fixed sections were dewaxed and rehydrated through 
a series of graded alcohols.  Sections were treated for 30 minutes with 0.6% hydrogen 
peroxide in methanol to destroy endogenous peroxidase prior to antigen retrieval.  
Antigen was retrieved either by microwaving sections for 10 minutes in 10mM sodium 
citrate buffer (MMP-9), or treatment with a [40ug/ml] solution of Proteinase K for 30 
minutes at room temperature (vWF).  Non-specific binding was inhibited by incubation 
in a blocking solution (10mM Tris-HCl pH7.4, 0.1M MgCl2, 0.5% Tween20, 1% BSA, 
5% Serum) for 1hr at room temperature.  Rabbit polyclonal anti-mouse MMP-9 (used at 
1:250 dilution) (Abcam, Cambridge, MA) or rabbit anti-human vWF antibodies (1:1000 
dilution) (Dako), were diluted in blocking solution and applied at 4° C overnight.  
Appropriate IgG controls were used on adjacent sections to evaluate background staining.  
Sections were washed with TBS (150mM NaCl, 10mM Tris) and incubated with 
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appropriate biotinylated secondary antibody for 1hr at room temperature.  Positive cells 
were visualized with an avidin-biotin peroxidase complex (Vectastain Avidin-Biotin 
Complex kit, Vector Laboratories, Burlingame, CA) and 3,3’-diaminobenzidine 
tetrahydrochloride substrate (Sigma).  Nuclei were counterstained with Mayer’s 
hematoxylin (Sigma), washed in TBS, dehydrated through alcohols, cleared in xylenes 
and mounted. 
 
Immunohistochemical Quantification 
Metamorph software (Molecular Devices, Downingtown, PA) was used to 
measure vWF staining intensity.  Three sections from five each MMP-9 null and wild 
type littermate mice were analyzed for positive staining area per total area and reported as 
percent.  Groups were compared using a two-tailed t test. 
 
Immunofluorescent Colocalization of MMP-9 and Leukocyte Markers 
Five micron, paraffin embedded, formalin fixed sections were dewaxed and rehydrated 
through alcohols.  Sections were microwaved in a 10mM sodium citrate solution to 
retrieve antigen for 10 minutes and allowed to cool.  Non-specific staining was prevented 
by treating sections with a blocking solution for 1 hour at room temperature.  Sections 
were simultaneously treated with a rabbit polyclonal antibody to detect MMP-9 and an 
antibody to detect leukocytes for 6 hours at room temperature.  Neutrophils were stained 
using a monoclonal rat anti-neutrophil antibody (AbD Serotec, Oxford, UK).  B cells 
were visualized using a rat monoclonal antibody recognizing CD45R/B220 (AbD 
Serotec).  Macrophages were demonstrated by staining for F4/80 antigen using a rat 
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monoclonal antibody (AbD Serotec).  Sections were washed in PBS, and incubated with 
fluorescently labeled secondary antibodies (Molecular Probes, Carlsbad, CA) and DAPI 
to visualize nuclei then mounted in aqueous mounting media (Biomeda, Foster City, CA). 
54 
 
CHAPTER III 
 
RESULTS 
 
MMPs in Mouse Models of Colon Cancer 
 MMPs are widely expressed by a variety of neoplasms.  Previously, we have 
investigated the expression of various MMP family members in the development of 
intestinal adenomas using different mouse models of intestinal tumorigenesis.  Strikingly, 
genetic ablation of MMP-7, an epithelially expressed MMP-7, reduced tumor multiplicity 
by 58% in the Min mouse model.  Furthermore, analysis of tumors from these animals by 
in situ hybridization revealed that like human tumors, murine tumors express MMPs-2, -
3, -7, -10, and -13 (Wilson et al., 1997).  While only a subset of tumors normally 
expressed MMP-2, upon genetic ablation of MMP-7, all tumors that formed were found 
to express MMP-2 (Table 3).  However, since our initial screen, several additional MMP 
family members have been identified.  Many of these MMPs have been detected in 
tumors.  We sought to generate a comprehensive profile of MMPs expressed by normal 
murine small intestine and intestinal adenomas that we could then use to identify targets 
for further study. 
 
Microarray Profiling of Intestinal Adenomas 
 The development of microarray technology has allowed an investigator to 
compare the expression of thousands of genes simultaneously.  Microarray based analysis 
uses thousands of unique cDNA or oligonucleotide probe sequences that are spotted onto  
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Table 3:  Expression analysis of MMPs expressed in Min tumors as previously 
determined by in situ hybridization.  (Wilson et al., 1997) 
 
 
 
microscope slides.  Depending on the commercial platform used, purified mRNA is then 
converted into fluorescently labeled cDNA (spotted arrays) or cRNA (Affymetrix based 
arrays).  For traditional spotted arrays, samples to be compared are labeled with different 
fluorophores, hybridized to the same slide, and the difference in hybridization between 
samples is detected by laser scanning.  Alternatively, oligonucleotide based arrays such 
as the Affymetrix platform, require each sample to be hybridized to an individual array, 
and hybridization between arrays is compared (Figure 5) (Bucca et al., 2004; Staal et al., 
2003).   
 To generate a profile of which MMPs are differentially expressed in intestinal 
tumors, we developed two separate microarrays capable of distinguishing between highly 
homologous sequences.  Initially, I subcloned fragments of all human and mouse MMPs 
and TIMPs capable of distinguishing between orthologous sequences for the construction 
of a cDNA array.  Additionally, in conjunction with the Protease Consortium, I aided in  
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Figure 5:  Comparison of traditional glass slide cDNA microarrays to the 
Affymetrix Gene Chip platform.  Isolated RNA is labeled by in vitro transcription with 
either fluorescent dyes (Glass slide arrays) or biotin (Affymetrix) labeled nucleotides 
prior to hybridization to an array containing thousands of genes.  Hybridization intensity 
is determined by laser scanning.  For traditional array analysis the ratio between sample 
intensity is compared, whereas with Affymetrix arrays hybridization intensity between 
samples is compared using for individual Gene Chips per sample (Staal et al., 2003). 
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the construction of a novel dual-species Affymetrix array also capable of distinguishing 
closely related orthologues (Schwartz et al., 2007).  Tissue was harvested from normal 
small intestine and tumors from the ilea of Min mice and stored overnight in RNAlater, a 
mild fixative that has been demonstrated to stabilize RNA and improve yield.  Total RNA 
was isolated from tissue by using a rotor-stator homogenizer and RNeasy mini kit 
(Qiagen).  RNA concentration and integrity were assessed using UV spectrophotometry, 
and samples with a 260/280 absorbance ration of 1.95-2.05 were submitted to the 
Vanderbilt Microarray Shared Resource (VMSR) for cDNA transcription, labeling, 
hybridization, and microarray scanning.  Two adenoma samples were compared on our 
cDNA array to a common normal sample, and an intensity ratio was determined by 
ArrayAssist Lite software (Table 4).  Alternatively, multiple samples were compared 
using a novel Affymetrix array containing probes for all currently known human and 
murine proteinases. 
Because of the high degree of divergence observed between samples as assayed 
on the cDNA array, as well as the enhanced ability of the Affymetrix array to distinguish 
signal versus noise and the availability of a greatly expanded probe set, we opted to 
continue our studies using the Affymetrix platform rather than spotted arrays.  Additional 
samples were isolated and assayed using the Affymetrix Hu/Mu ProtIn array using both 
absolute and relative analysis.  Relative analysis identified MMP-10, -13, and -14 as 
significantly more abundantly expressed in tumor tissue than normal intestine, a finding 
also reported by others (Martinez et al., 2005).  Additionally, comparing absolute analysis 
calls between groups revealed MMP-9 and -12 as present in tumor tissue, but  
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Table 4:  Expression analysis of MMP family members in tumor tissue compared to 
normal ileum.  Total RNA was isolated from ileal tumors and normal small intestine of 
Min mice as described in the Materials and Methods.  Microarray analysis was performed 
using a custom created cDNA microarray by the VMSR.  Numbers indicate fold change 
of hybridization intensity, with positive numbers indicative of increased expression in 
tumor samples and negative numbers indicative of less abundant transcript in tumor. 
 
 
 
59 
 
Table  5:  Affymetrix microarray analysis of MMP family members from normal 
ilea and intestinal tumors.  Four samples of normal ileal tissue were compared to six 
pools of adenomas isolated from Min mice and compared using a novel Affymetrix 
microarray by relative and absolute analysis.  Relative analysis revealed that transcripts 
for MMP-10, -13, and -14 are more abundant in tumor tissue than normal intestine.  
Absolute analysis identified MMP-9 and -12 as expressed in tumor, but not in normal 
intestine. 
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absent from normal intestine (Table  5).  Generally, the expression profile generated by 
Affymetrix analyses was more similar to the cDNA profile generated for Mouse B, 
though methodological differences between the two techniques minimize the utility of 
such a comparison.  
  To confirm our microarray findings we used real-time PCR analysis, which 
allows relative quantification of the abundance of target genes across samples.  Real-time 
PCR was performed on all samples submitted for Affymetrix microarray analysis, and 
relative abundance of transcripts for MMPs-10, -12, and -13 was determined in 
comparison to GAPDH, a housekeeping gene with relatively stable expression across 
cells.  Primers for MMP-9 and -14 did not produce reliable results.  Using an algorithm 
built into the PCR machine software package (BioRad iQ 4) levels of transcripts were 
quantified.  Thus, microarray results were validated by Real Time PCR, confirming that 
MMPs-10, -12, and -13 are differentially expressed in tumor samples (Figure 6).  These 
results have identified MMPs-9, -10, -12, -13, -14, and -15 as MMPs that are expressed 
differentially by intestinal adenomas. 
 
Analysis of Heterogeneity of MMP Expression in Min Tumors 
 
Previously, it has been shown that ablation of specific MMPs results in alterations 
of the expression of other MMP family members (Rodgers et al., 1994; Rudolph-Owen et 
al., 1997).  Because of the variation in MMP expression between tumors and apparent 
expressional compensation of MMP-2 previously observed (Wilson et al., 1997), I 
hypothesized that individual tumors may express different subsets of MMPs, and in mice  
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 Figure 6:  Relative expression analysis of selected MMPs in intestinal adenoma 
tissue compared to normal intestine.  Real time PCR was used to validate microarray 
analysis.  Abundance of transcripts for selected MMPs was compared to GAPDH, and 
results are reported as a ratio compared to normal tissue.  PCR to detect MMP-9 and -14, 
two other genes found to be differentially expressed was also performed, but did not 
produce measurable product. 
 
 
 
 
with particular MMPs genetically ablated, that presence of other MMP family members 
is able to compensate for this and would be detectable by relative expression analysis. 
The construction of the Affymetrix protease array provided a unique opportunity 
to assay both the absolute presence of transcript as well as quantification of “present” 
transcripts.  To test my hypothesis, I isolated individual tumors from wild type, MMP-7 
deficient, and MMP-2; MMP-7 double deficient animals.  Relative analysis across 
samples did not detect any significant variations within groups, and across groups the 
only difference detected was a decrease in the abundance of transcripts for MMP-7 and 
MMP-2 in animals with those MMPs genetically ablated.  Absolute analysis of samples 
revealed that in contrast to the hypothesis, tumors were very homogeneous in their 
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expression of MMPs (Table 6).  The only difference detected between groups by absolute 
analysis was that “present” signal for MMP-8 was detected in all tumors from all mice 
lacking MMP-7, but in only one out of six tumors assayed from wild-type Min mouse.  
MMP-8 is largely produced by neutrophils, and the presence of this transcript  
 
Table 6:  Tumors from wild-type and mice lacking MMP-7 or MMP-2 and MMP-7 
do not exhibit variability in their expression of MMPs.  To examine the possibility 
that MMP ablation resulted in transcriptional compensation of other MMP family 
members, microarray analysis was used to assay the expression of all MMPs in mouse 
tumors.  No significant variation within sets was observed, though all tumors examined 
from mice lacking MMP-7 expressed transcript encoding MMP-8, which was detected in 
only one tumor from wild type Min. 
 
 
 
 
 
63 
 
may indicate enhanced neutrophil infiltration into tumors from mice lacking MMP-7.  
Expression analysis using real time PCR analysis produced similar results (data not 
shown).  From these findings we can conclude that transcriptional compensation does not 
occur in the context of the intestinal adenomas that form in Min mice. 
Data presented here have expanded the spectrum of MMP family members shown 
to be expressed in intestinal adenomas.  Profiling of tumors using a novel Affymetrix 
microarray has largely mirrored our previously generated profile generated by in situ 
hybridaztion, with a few additions.  MMP-3, detected in roughly half of tumors by in situ 
hybridization was not regularly detected by absolute microarray analysis; however, this 
may be due to methodological assumptions used by this method.  Absolute analysis uses 
a proprietary algorithm to compare the ratio of binding to “perfect match” probes to 
“mismatch” probes, which other than a single base substitution at position 13 are 
sequentially identical (Staal et al., 2003).  False absent calls are favored by this approach 
as high background and sequentially homologous genes tend to increase the mismatch 
signal.   
MMP-7, another gene we previously detected as differentially expressed in tumor 
was not found to be differentially expressed using either absolute or relative analysis.  
However, our previous data looked at expression of only epithelial cells rather than whole 
tumor.  Paneth cells normally produce this MMP, so it is not surprising that absolute 
analysis did not detect a difference.  While the relative transcript abundance was 
increased in tumor, this gives no detail to the cellular origin of the transcript, and if this 
experiment were to be repeated using laser captured epithelial cells only, I would expect 
a difference to be obvious. 
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An interesting finding of these experiments is the modulation of expression of 
MMP-9 and -12.  Both of these MMPs are largely produced by inflammatory cells (Noel 
et al., 2008), thus enhanced expression observed in tumor tissue may simply be a 
reflection of leukocyte infiltration into the tumor, a concept further explored later in this 
chapter.  Enhanced expression of MMPs-10 and -13 in intestinal adenomas of the Min 
mouse has previously been reported (Martinez et al., 2005; Wilson et al., 1997).  Both of 
these MMPs have previously been shown to be produced by stromal cells within the 
tumor, though the functional consequence of this expression is unknown.  Based upon 
previous data and the results from my microarray screen, I chose to further examine the 
role of MMPs-2, -9, -10, -12, -13, and -19 in tumorigenesis using the Min mouse model. 
 
The Role of MMP-2 in Intestinal Tumorigenesis 
 Previously, we have demonstrated that genetic ablation of MMP-7 reduces tumor 
multiplicity by 58% in the Min mouse.  Additionally, while only a subset of wildtype 
Min tumors normally express MMP-2, upon genetic ablation of MMP-7 the reduced 
number of tumors that develop all express MMP-2, suggesting that MMP-2 may 
functionally compensate for MMP-7 in the development of intestinal tumors.  To 
examine this possibility we used selective breeding to develop a MMP-2 deficient Min 
mouse. 
   
Female MMP-2 deficient mice were crossed with male Min mice to generate mice 
heterozygous for MMP-2.  Two heterozygotes were crossed carrying the Min allele along 
the parental lineage in order to generate littermate mice that are either deficient, 
heterozygous or wild-type for MMP-2.  Mouse genotype at the MMP-2 and APC loci  
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 Figure 7:  MMP-2 ablation does not affect tumor multiplicity or size in the Min 
model.  (A)  Tumor multiplicity in MMP-2 deficient Min mice (35.7 tumors/mouse) was 
similar to that of wild-type (36.3 tumors/mouse) and heterozygous (41.7 tumors/mouse) 
littermates.  Difference is not statistically significant, Mann-Whitney t test.  (B)  Tumors 
from MMP-2 deficient mice are of similar size distribution to tumors from wild type 
littermates.  Least squares estimate of average tumor diameter found that the typical 
tumor from a MMP-2 deficient mouse was 1.1mm, while wild-type littermates was 
0.95mm.  Difference is not statistically significant, mixed model ANOVA analysis. (C)  
Overlay of trace from panel B.  Dashed lines represent individual mice, solid lines 
represent average tumor distribution. 
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were analyzed by PCR analysis.  Mice with MMP-2 genetically ablated developed a 
similar number of tumors to wild-type and heterozygous littermate controls (Figure 7A).  
Further, ablation of MMP-2 did not affect either spatial distribution of tumors within the 
intestine, nor size (Figure 7B-C). 
 Previous data suggest that while MMP-7 is a key mediator of tumorigenesis, 
MMP-2 may be able to functionally compensate for ablation of MMP-7.  To examine this 
possibility we developed MMP-2; MMP-7 double deficient mice.  In contrast to 
previously published results, MMP-7 deficient Min mice did not develop statistically 
fewer tumors than wild-type Min littermates.  However, unlike previous studies, separate 
lineages derived from a common progenitor were compared rather than littermates, which 
could generate divergent lines within the sample pool.  Although a conservative breeding 
strategy was utilized in an attempt to minimize divergence, I cannot exclude this as an 
explanation for the variability observed.  Additionally, at the time when this pilot study 
was conducted a syndrome of unknown etiology arose within several lineages of the 
mouse colony that manifested in hydronephrotic kidneys, extraordinary variability in 
tumor burden, increased juvenile mortality, and frequent gastrointestinal inflammation as 
determined by gross necropsy.  Mice displaying any of these symptoms were excluded 
from analysis, which severely limited our sample pool of wild-type Min and MMP-7 
deficient Min mice.  Regardless, tumor multiplicity was similar in mice lacking both  
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 Figure 8:  Effect of ablating both MMP-2 and MMP-7 in the Min model.  Because of 
the potential for MMP-2 and -7 to functionally compensate for each other, we created 
mice lacking both of these MMPs.  No further reduction in tumor multiplicity was 
observed when compared to MMP-7 deficient animals suggesting that MMP-2 does not 
significantly contribute to adenoma formation in the Min model. 
 
 
 
 
MMP-2 and MMP-7 when compared to wild-type or MMP-7 deficient littermates (Figure 
8), and was similar to historical data comparing MMP-7 deficient Min mice.  Taken 
together, all these data suggest that MMP-2 does not significantly contribute to the 
development of intestinal adenomas in the Min model. 
 
The Role of MMP-12 in Intestinal Tumorigenesis 
 MMP-12 was one of two MMPs differentially detected by absolute microarray 
analysis as absent in normal intestinal tissue, but present in adenomas.  High levels of 
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macrophage derived MMP-12 is commonly associated with an improved prognosis in 
colorectal tumors (Asano et al., 2007; Zucker and Vacirca, 2004).  Because of these 
changes, we postulated that MMP-12 functionally acts to inhibit tumor development, and 
that genetic ablation of this gene would result in a significant enhancement of tumor 
multiplicity, size and progression.   
Male Min mice and female MMP-12 deficient mice on the C57BL/6 background 
were purchased from the Jackson Lab and crossed to generate pups heterozygous for 
MMP-12.  Wild type and heterozygous control Min mice developed an average of 
35.2±14.9 and 54.3±21.6 tumors per mouse, respectively.  In comparison, Min mice 
lacking MMP-12 developed an average of 44.0 ±23.9 tumors per mouse, not a 
statistically significant difference (Figure 9A).  Similarly, the average tumor diameter 
was not significantly different between from wild-type control (1.1mm) and MMP-12 
deficient (1.2mm) animals (Figure 9B-C). 
Taken together, these data suggest that while MMP-12 expression has been shown 
to predict a good prognosis, genetic ablation does not affect early stage tumorigenesis.  
However, while MMP-12 may be functionally protective during later stages of tumor 
progression, we could not assess such using the current model system.  Alternatively, 
high macrophage density within colorectal tumors has also been shown to be an indicator 
of positive prognosis (Forssell et al., 2007).  While macrophages are abundant throughout 
human tumors, they tend to localize peritumorally in Min adenomas, and MMP-12 may 
simply be acting as a marker for macrophages in the context of human intestinal 
adenomas.   
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 Figure 9.  MMP-12 ablation does not affect tumor multiplicity or size in the Min 
model.  (A)  Tumor multiplicity in MMP-12 deficient Min mice (44.0 tumors/mouse) 
was similar to that of wild-type (35.2 tumors/mouse) and heterozygous (54.3 
tumors/mouse) littermates.  Difference is not statistically significant, Mann-Whitney t 
test.  (B)  Tumors from MMP-12 deficient mice are of similar size distribution to tumors 
from wild type littermates.  Least squares estimate of average tumor diameter found that 
the typical tumor from a MMP-12 deficient mouse was 1.2mm, while wild-type 
littermates was 1.1mm.  Difference is not statistically significant, mixed model ANOVA 
analysis. (C)  Overlay of trace from panel B.  Dashed lines represent individual mice, 
solid lines represent average tumor distribution. 
 
70 
 
The Role of MMP-19 in Intestinal Tumorigenesis 
 MMP-19 has been detected on the surface of activated peripheral blood 
mononuclear cells, TH1 lymphocytes (Sedlacek et al., 1998), and is normally expressed 
throughout the intestine in both enterocytes (Mueller et al., 2000) and occasional stromal 
fibroblasts and macrophages, though expression by intestinal epithelial cells is decreased 
upon transformation suggesting a role in enterocyte shedding (Bister et al., 2004).  
Microarray analysis detected only a weak presence of transcripts for MMP-19 in normal 
tissue, yet in two tumor samples transcripts were found.  Because of these seemingly 
disparate findings, we examined the effect of MMP-19 ablation in the Min model.  We 
hypothesized that if MMP-19 was functioning in a protective role, then ablation of MMP-
19 would enhance tumorigenesis, with deficient animals developing more tumors and 
tumors that are larger in size.  Male Min mice and female MMP-19 deficient mice on the 
C57BL/6 background were obtained from J. Caterina and crossed to generate pups 
heterozygous for MMP-19.  Min mice lacking MMP-19 developed an average of 41.0 
±19.8 tumors per mouse, whereas wild type and heterozygous control Min mice 
developed an average of 49.7±28.9 and 35.1±10.8 tumors per mouse, respectively (Figure 
10A).  Similarly, the average tumor diameter was not significantly different between 
wild-type control (1.0mm) and MMP-19 deficient (1.0mm) animals (Figure 10B-C). 
Taken together, these data suggest that MMP-19 does not significantly contribute 
to intestinal tumorigenesis in the Min model despite the apparent expression difference.  
Given that MMP-19 has been detected on the surface of various lymphocytes, it is 
possible that the difference observed in transcript abundance is due to differential TH1 
infiltration. 
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 Figure 10:  MMP-19 ablation does not affect tumor multiplicity or size in the Min 
model.  (A)  Tumor multiplicity in MMP-19 deficient Min mice (41.0 tumors/mouse) 
was similar to that of wild-type (49.7 tumors/mouse) and heterozygous (35.1 
tumors/mouse) littermates.  Difference is not statistically significant, Mann-Whitney  t 
test.  (B)  Least squares estimate of average tumor diameter found that the typical tumor 
from both MMP-19 deficient and wild-type littermates was 1.0mm.  Difference is not 
statistically significant, mixed model ANOVA analysis. (C)  Overlay of trace from panel 
B.  Dashed lines represent individual mice, solid lines represent average tumor 
distribution. 
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The Role of MMP-9 in Intestinal Tumorigenesis 
 
 Transcripts encoding the proteinase MMP-9, like MMP-12, were absent from 
normal tissue, but abundantly expressed in tumor.  MMP-9 is produced by several 
stromal cell populations including neutrophils, mast cells, macrophages, fibroblasts, as 
well as by the tumor epithelial cells directly (Noel et al., 2008).  Previous studies using 
mice with MMP-9 genetically ablated have shown that MMP-9 deficient animals develop 
fewer tumors than do littermate controls, but those tumors that do develop are more 
aggressive and of a more advanced phenotype (Coussens et al., 2000).  While an 
excellent model of early stage tumorigenesis, the Min model is limited in that tumors that 
develop rarely invade and never metastasize.  Because of the seeming dual role of MMP-
9 in both promoting tumorigenesis but inhibiting tumor progression, we hypothesized that 
MMP-9 ablation in the Min mouse would decrease tumor multiplicity, but that those 
tumors that formed may be larger or more progressed as determined by the presence of 
local invasion or distant metastasis. 
 MMP-9 deficient Min mice were developed by crossing male Min mice to MMP-
9 deficient females, obtained from Z. Werb.  Mice lacking MMP-9 developed 26.5±17.7 
tumors on average.  In comparison, wild-type littermate Min mice developed 35.0±26.1, 
and heterozygotes 32.9±16.2 (Figure 11A).  This decrease indicates a 25% reduction in 
tumor multiplicity in MMP-9 deficient animals.   
Tumors that arose in MMP-9 deficient animals were further characterized for 
phenotypic differences.  Average tumor diameter was similar between MMP-9 deficient 
and wild-type Min littermates (Figure 11B-C), suggesting that MMP-9 ablation affected 
tumor  
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Figure 11:  MMP-9 ablation does not affect tumor multiplicity or size in the Min 
model.  (A)  Tumor multiplicity in MMP-9 deficient Min mice (26.5 tumors/mouse) was 
significantly reduced in comparison to wild-type (35.0 tumors/mouse) and heterozygous 
(32.9 tumors/mouse) littermates.  p=0.0440, Difference is statistically significant, Mann-
Whitney t test.  (B)  Tumors from MMP-9 deficient mice are of similar size distribution 
to tumors from wild type littermates.  Least squares estimate of average tumor diameter 
found that the typical tumor from a MMP-9 deficient mouse was 1.0mm, while wild-type 
littermates was 1.0mm.  Difference is not statistically significant, mixed model ANOVA 
analysis. (C)  Overlay of trace from panel B.  Dashed lines represent individual mice, 
solid lines represent average tumor distribution. 
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incidence, but not tumor growth.  MMP-9 expression has been observed in several cell 
types, including tumor epithelial cells.  To identify the cellular source of MMP-9 in these 
tumors, immunohistochemical staining was employed.  MMP-9 staining was not 
observed in any epithelial cells, but was abundantly detected throughout stromal and 
intravascular cells, suggesting that intratumoral MMP-9 was of leukocyte origin (Figure 
12).  To further examine this, I performed immunofluorescent co-localization using 
markers for different leukocyte populations. All intratumoral MMP-9 positive cells co-
stained with an antibody that specifically recognized neutrophils.  A single MMP-9 
positive macrophage was observed at the tumor periphery, and none were detected 
intratumorally (Figure 13).  No MMP-9 positive B lymphocytes were detected.  Because 
MMP-9 staining localized to neutrophils, we examined intratumoral neutrophil 
abundance in both wild-type and MMP-9 deficient Min mice.  Neutrophils were equally 
abundant in tumors from both groups (Figure 14).   
 
 Neutrophil derived MMP-9 has been shown to be a critical mediator of 
angiogenesis (Ardi et al., 2007; Nozawa et al., 2006).  To determine if MMP-9 deficiency 
resulted in less vascularized tumors, we employed immunohistochemical staining to 
detect total (von Willebrand Factor) and angiogenic (CD-31) vasculature in tumors from 
MMP-9 deficient animals and littermate controls.  Initial experiments indicated that 
tumors from wild type mice on average had twice as much total vasculature as measured 
by immunohistochemistry for vWF, a marker of total vasculature; however  
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 Figure 12:  MMP-9 localization by immunohistochemical staining.  A:  A monoclonal 
antibody raised to react with murine MMP-9 demonstrated abundant stromal cells were 
positive for MMP-9 (brown staining, hematoxylin counterstain).  Scale bar indicates 
40μm.   B:  Serotype control antibody produced no positive staining.  Scale bar indicates 
40μm. 
 
 
 
 
 
Figure 13:  Imunofluorescent co-staining of MMP-9 and Leukocyte Markers.  To 
further determine the cell populations producing intratumoral MMP-9, fluorescent co-
staining was used to visualize (A) neutrophils (anti-neutrophil), (B) macrophages (F4/80) 
and (C) B lymphocytes (B220).  All intratumoral MMP-9 was of neutrophil origin, while 
one MMP-9 positive macrophage was observed at peri-tumorally.  No MMP-9 positive B 
cells were observed.   
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Figure 14:  Neutrophil density is similar in tumors from wild type and MMP-9 
deficient tumors.  Immunohistochemical staining for neutrophils was performed on 
tumors from 5 each MMP-9 deficient mice and wild type littermates.  Percent positive 
area was calculated using MetaMorph software by first masking an area of interest, and 
then quantifying positive pixels per total pixels. 
 
 
this finding was not supported in follow up experiments using larger data sets.  Repeated 
Taken together, these studies indicate that like epithelial produced MMP-7, neutrophil 
derived MMP-9 functions in a pro-tumorigenic capacity early in the development of 
intestinal tumors.  
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CHAPTER IV 
 
AN ANTI-TUMORIGENIC ROLE FOR MAST CELLS 
 
Introduction 
 Mast cells are a group of bone marrow derived granulocytes most commonly 
associated with allergy, though recent studies show them to be involved in a wide range 
of physiological and pathological processes (Leslie, 2007).  Classically, mast cells are 
divided into two sub-populations based upon their histochemical properties and 
anatomical distribution (Hallgren and Gurish, 2007).  Connective-tissue mast cells 
(CTMCs) are found throughout the skin, peritoneum and intestinal submucosa, while 
mucosal mast cells (MMCs) are found throughout the epithelial surface of the lung and 
intestinal mucosa (Miller and Pemberton, 2002).  In addition to anatomical distribution, 
these two broad classes of mast cells also differ in their expression of tryptases and 
chymases (Caughey, 2007).  Generally, MMC tend to express both chymases and 
tryptases, while CTMC express only tryptases, though recent evidence suggests that mast 
cell heterogeneity is broader than just the two classically defined groups (Caughey, 
2007). 
Mast cell activation, typically by IgE receptor cross-linkage or Toll-like receptor (TLR) 
binding (Metz et al., 2007), induces mast cells to secrete various pro-inflammatory 
mediators (Bischoff and Kramer, 2007).  These mediators include cytokines and small 
molecules involved in leukocyte recruitment and activation, vasodilation, angiogenesis, 
and mitogenesis (Frankenstein et al., 2006; Theoharides et al., 2007).  Conversely, in 
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some circumstances, mast cells have been demonstrated to limit inflammation, and many 
mast cell secreted mediators have both pro- and anti-inflammatory aspects indicating a 
central role for mast cells in modulating inflammation (Metz et al., 2007).  Increased 
abundance of mast cells has been observed in various human tumors, and is frequently 
associated with a good prognosis (Hedstrom et al., 2007; Rajput et al., 2007).   
Results of microarray profiling of intestinal adenomas, revealed a striking 
increase in the abundance of mast cell expressed transcripts as reported here.  Because of 
the well established role of inflammation in the development and progression of 
colorectal neoplasms (Clevers, 2004), we generated a mast cell-deficient Min mouse to 
examine the role of mast cells in the early stages of intestinal tumorigenesis.   
 
Results 
 
Mast cells are present in intestinal adenomas of Min mice 
As part of a broader screen to determine which proteinases were differentially 
expressed in Min adenomas compared to normal murine small intestine, we used the 
Hu/Mu ProtIn microarray from Affymetrix that contains probe sets for all known human 
and murine proteinases (Schwartz et al., 2007).  Numerous mast cell related transcripts 
were more abundant in tumor tissue than in normal distal small intestine (Table 7).    
Real-time PCR analysis of murine mast cell protease (mcpt) transcripts was performed to 
validate microarray findings, and mcpt-1, -2, -5, -6 and -7 transcripts were found to be 
significantly more abundant in adenomas than normal tissue (Figure 15). 
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Table 7:  List of 31 genes differentially expressed in intestinal adenomas of Min mice 
as compared to normal intestinal tissue.  Microarray profiling intestinal adenomas 
using a novel Affymetrix Hu/Mu ProtIn chip revealed 31 genes that significantly 
differentially expressed as revealed by relative microarray analysis.  Several mast cell 
related transcripts were identified from this screen as indicated by gray shading.  Positive 
Log2 ratio indicates genes more abundant in tumor, while negative rations indicate genes 
more abundant in normal tissue. 
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 Figure 15:  Relative expression analysis of mast cell proteases in intestinal adenoma 
tissue compared to normal intestine.  Real time PCR was used to validate microarray 
results indicating an increase in the abundance of several mast cell proteinase transcripts 
in intestinal adenomas.  Abundance of transcripts for mcpt genes was compared to 
GAPDH, and results are reported as a ratio compared to normal tissue.  Black bars 
represent chymase family members, and gray bars represent tryptase family members.  
Reactions were run for six tumor samples and four normal controls in triplicate.  Fold 
change was determined in comparison to change in GAPDH.  *, P<0.05; **, P<0.005.    
 
 
To examine the distribution of mast cells within tumors, chloroacetate staining 
was performed to demonstrate chymase, a marker of mucosal mast cells (Leder, 1979).  
Mast cells were only occasionally present in normal intestinal tissue, and when present, 
were restricted to the base of the villus.  However, in tissue isolated from tumors, mast 
cells were found throughout the tumor and surrounding stroma (Figure 16A-D).  As 
previously observed in a chemical-induced model of colorectal tumorigenesis 
(Wedemeyer and Galli, 2005), mast cell density was enhanced in tumor tissue compared 
to normal small intestine (Figure 16E).    Combined, these observations demonstrate that 
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mast cell distribution is changed and abundance is increased in both benign and 
malignant tumor tissue.   
 
 
 
Figure 16:  Mast cells are more abundant in adenomas from Min mice than normal 
murine small intestine.  A-D:  Histochemical staining for chymase.  Leder’s esterase 
reaction was employed to visualize mast cells (dark blue stain) in normal small intestine 
at low (A, scale bar 150μm) and high power (B, scale bar indicates 50μm) and tumor in 
low (C, scale bar 320μm) and high power (D, scale bar indicates 50μm).  Tissue was 
counterstained with Kernetrocht’s nuclear red.  E:  Abundance of chymase positive cells 
was measured in normal and tumor tissue.  Significantly more chymase positive cells 
were found in tumor tissue than normal controls.  Multiple sections of individual tumors 
and normal small intestine were counted from four each Min mice and wild-type 
littermate controls.  Each point represents an individual measurement; hash mark, mean.  
**, P<0.005, difference is statistically significant, Student’s two-tailed t test.   
 
 
 
Mast cell ablation results in increased tumor multiplicity and size 
Previously, epidemiological studies have linked high numbers of infiltrating mast 
cells into tumors with a positive prognosis (Hedstrom et al., 2007; Rajput et al., 2007); 
hence the hypothesis was that the increase in mast cell density was evidence of a host 
response to the tumor.  To test this possibility we used a genetic approach. 
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To examine the role of mast cells in intestinal tumorigenesis, we generated Min-
Sash (APCMin/+;c-kitW-sh/W-sh) mice. Mice homozygous for the W-sh allele at the c-kit 
locus lack mucosal mast cells, though unlike the phenotypically similar c-kit W/W-v 
mutants, Sash mice are not sterile, nor anemic, have normal levels of intestinal TCRγδ T 
cells (Metz and Maurer, 2007), and are easily genotyped based upon their coat color 
(Figure 17).   
 
 
 
Figure 17:  Sash mutants are easily genotyped based upon coat color.  Sash mice, a c-
kit mutant, are named for the characteristic white “sash” seen in heterozygous mice on 
the C57Bl/6 background.  Wild type mice have a normal coat color, while mice 
homozygous for the W-sh allele are white due to a defect in melanocyte survival. 
 
 
 
 
 
Mice were raised on a high-fat diet, which has been shown to enhance intestinal 
tumorigenesis (van Kranen et al., 1998), and were euthanized at 17 weeks of age.  On 
average, Min-Sash mice developed 52.8 tumors while Min littermates developed 38, 
representative of a 36% increase on average of tumor multiplicity when mast cells are 
absent (Figure 18A).  Additionally, tumor diameter was 33% larger in Min-Sash mice  
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 Figure 18:  Tumor multiplicity in the small intestine in mice generated from an 
APCMin/+-c-kitW-sh/W-sh cross.  A:  Min-Sash (APCMin/+;c-kitW-sh/W-sh) mice develop 
significantly more tumors than Min littermates at 17 weeks of age.  A total of 50 Min 
mice, 16 homozygous for the W-sh allele, 17 heterozygous for the W-sh allele, and 17 
wild-type for the W-sh allele mice were counted for tumors; hash mark, mean.  
**,P<0.005; ***, P<0.0005, differences are statistically significant, Poisson regression.  
B:  Size distribution of min adenomas from wild-type (gray) and Min-Sash (black) mice.  
Tumors were measured with digital calipers from four Min-Sash mice (n=209) and five 
Min (n=213) littermate controls.  Tumors from a total of 10 mice, 4 Min-Sash 
(homozygous for the W-sh allele), 1 heterozygous for the W-sh allele and 5 wild-type 
were measured.  Min-Sash mice develop significantly larger tumors than wild-type 
littermates, P<0.05, difference is statistically significant, repeated measures ANOVA test. 
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than in Min littermates (Figure 18B).  These findings suggest a protective role for mast 
cells in intestinal tumorigenesis. 
 
Mast cell deficiency impairs apoptosis of tumor cells 
Because tumors were found to be both more numerous and larger in Min-Sash 
mice, we examined tumor cell proliferation and apoptosis.  Proliferation was assayed by 
immunohistochemical staining for phospho-Histone H3, a marker specific for late 
anaphase and mid-metaphase mitosis (Hendzel et al., 1997).  Proliferation was not 
statistically different between Min-Sash and Min litter mates (Figure 19A and 19B).  
BrdU incorporation, a marker of DNA synthesis, produced similar results (Figure 20A).  
To assess apoptosis, tumors were sectioned and immunohistochemically stained for 
cleaved caspase-3, and positive cells per unit area were compared.  Tumors from Sash 
mice had 33% fewer apoptotic nuclei per unit area than wild type controls (Figure 19C 
and 19D).  TUNEL staining produced similar results (Figure 20B).  The effect of mast 
cell ablation on adenoma formation and growth was therefore likely due to effects on 
adenoma cell apoptosis. 
 
Tumors from mast cell deficient mice have reduced eosinophil infiltrate 
Mast cells have been shown to induce apoptosis through signaling to other 
immune cells.  To determine if the observed difference in apoptosis was the result of 
differential immune cell infiltration into the tumor, immunohistochemical staining for 
eosinophils, neutrophils, macrophages, and T cells was performed.  Eosinophils and 
neutrophils were found throughout the tumor and adjacent tissue of both Min and Min-  
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 Figure 19:  Apoptosis is inhibited in intestinal adenomas from Min-Sash mice 
compared to littermate controls; proliferation is not affected.  A:  Intestinal 
adenomas were assayed for proliferative cells by phospho-Histone H3 
immunohistochemistry.  Positive cells were counted per unit area using NIH ImageJ 
software; hash mark, mean, not significant.  B:  Phospho-histone H3 staining (dark 
brown staining) in tumors isolated from Min (top) and Min-Sash mice (bottom).  Nuclei 
were visualized by counterstaining with hematoxylin.  Scale bar indicates 100μm.  C:  
Intestinal adenomas were isolated from Min (n=7) and Min-Sash (n=7) littermates and 
stained for cleaved caspase-3, a marker of apoptosis.  Positive cells were counted per unit 
area as determined by NIH ImageJ software.  hash mark, mean  *, P<0.05, difference is 
statistically significant, Mann-Whitney two-tailed t test.  D:  High power 
photomicrograph of caspase-3 immunohistochemistry (dark brown stain) in tumors 
isolated from Min (top) and Min-Sash (bottom) mice (63x), scale bar represents 50μm.  
Nuclei were counterstained with Mayer’s hematoxylin. 
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 Figure 20:  Alternative quantification of proliferation and apoptosis performed by 
histochemistry for incorporated BrdU or TUNEL staining, respectively.   
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Figure 21:  Eosinophils are less abundant in adenomas from Min-Sash mice 
compared to wild-type littermates; other leukocyte populations are not affected.  
Intestinal adenomas were isolated from wild-type and Min-Sash littermates and profiled 
for leukocyte populations by immunohistochemical staining.  A:  Immunohistochemical 
demonstration of MBP-positive cells indicating eosinophils in wild-type (left) and Min-
Sash (center) mice.  Scale bar indicates 100 μm.  Quantitation of eosinophils in Min-Sash 
mice compared to Min controls (right); hash mark, mean, *, P<0.05, difference is 
statistically significant, Student’s two-tailed t-test.  B-C:  Immunohistochemical 
demonstration of neutrophils (anti-neutrophil+) (B) and T cells (CD3ε+) (C) in tumor 
tissue isolated from Min (left) and Min-Sash (center) mice.  No differences were detected 
between groups (right).   Scale bar indicates 100μm. 
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 Sash mice, however, fewer eosinophils were present in tumors of Min-Sash mice 
compared to Min littermates (Figure 21A).  No differences were detected in the number 
or distribution of neutrophils, (Figure 21B).  T cells were primarily detected adjacent to 
tumor with very few intratumoral cells, and no difference was detected between Min and 
Min-Sash mice (Figure 21C).  Macrophage staining was exceptionally sparse and 
virtually all macrophages detected were located in adjacent stromal tissue; no difference 
was detected between groups.  
To confirm that mast cells were responsible for this phenotype, we attempted to 
repopulate the gut with bone marrow derived mast cells.  To reconstitute intestinal mast 
cells into Min-Sash mice,1-week old Min and Min-Sash mice received a single i.p. 
injection of GFP tagged BMMC.  At 17 weeks of age mice were euthanized and 
intestines were harvested and tumor multiplicity and size were measured.  The presence 
of reconstituted mast cells was visualized by both GFP immunohistochemistry and direct 
GFP fluorescence.  GFP-positive mast cells were rarely detected in tumors from any of 
the mice, though abundant GFP-positive cells were observed in intestinal lymph nodes 
(Figure 22).  Since reconstituted mast cells did not appear to home to the tumors, at least 
at the 17 week time point, we asked if they altered the infiltration of endogenous mast 
cells or eosinophils to the tumors.  The abundance of intratumoral mast cells was not 
significantly different between treated and previously described untreated Min or Min-
Sash mice (Figure 23A).  Compared to untreated mice, the eosinophil density in Min-
Sash mice remained unchanged, but Min mice that received an injection of BMMC had a 
significantly increased density of intratumoral eosinophils (Figure 23B).  Interestingly,  
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 Figure 22.  Cultured bone marrow mast cells preferentially migrated to intestinal 
lymph nodes, but not tumors.  GFP tagged bone marrow mast cells were injected 
intraperitoneally into 1 week old Min-Sash pups in an effort to repopulate mucosal mast 
cells throughout the gut.  Mast cells (green) were visualized by direct 
immunofluorescence and only rarely detected in tumors (left), but were abundant 
throughout intestinal lymph nodes (right) and spleen.  Eosinophils (red) were detected 
with a monoclonal antibody to MBP and present throughout both tissues. 
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 Figure 23:  Bone marrow mast cell (BMMC) injection reduces adenoma formation 
in Min mice.  A:  Min mice treated with an intraperitoneal injection of bone marrow 
mast cells did not have an increased abundance of mast cells in tumors compared to non-
treated controls; bars, mean; Difference is not statistically significant, Student’s two-
tailed t test.  B:  Eosinophil density is not increased in tumors isolated from Min mice 
that received a BMMC injection compared to non-treated controls; bars, mean.  
Difference is not statistically significant, Student’s two-tailed t test.  C:  Tumor 
multiplicity in the small intestine is reduced in Min mice treated with an intraperitoneal 
injection of bone marrow mast cells (BMMC->Min) compared to untreated controls.  
***, P<0.0005, difference is statistically significant, Poisson regression. 
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Min mice that received a single i.p. injection of mast cells developed 40% fewer 
tumors than previously described Min controls.  In contrast, BMMC treated Min-Sash 
mice did not develop significantly fewer tumors than untreated Min-Sash controls.  The 
difference in tumor multiplicity correlated positively with intratumoral eosinophil density 
(Figure 23C), suggesting a significant anti-tumor role for eosinophils. 
In summary, ablation of mast cells correlated with a decrease in tumor-infiltrating 
eosinophils but not of any other leukocyte lineage examined.  Overall, our results support 
a protective, anti-tumor role for mast cells and eosinophils in intestinal tumorigenesis and 
provide experimental validation of an epidemiological observation. 
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CHAPTER V 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
Discussion 
 
 The goal of the work described in this dissertation was to investigate the role of 
host derived proteinases in an animal model of early intestinal tumorigenesis.  In order to 
generate a comprehensive profile of all proteinases expressed by intestinal tumors of the 
Min mouse model system, we developed a custom Affymetrix microarray containing 
probes for all known human and murine proteinases.  Based upon the profile that was 
generated, I tested the effect of ablating various MMPs on tumor multiplicity in the Min 
system.  I have demonstrated that genetic ablation of MMP-2, -12, or -19 does not affect 
multiplicity or growth of intestinal adenomas in mice harboring the Min mutation.  
However, deleting MMP-9 significantly reduces tumor multiplicity in this model system, 
suggesting that MMP-9 plays a pro-tumorigenic role.  Furthermore, immunofluorescent 
co-staining has identified neutrophils as the major cellular source of MMP-9 in these 
tumors.  Additionally, using this microarray I detected an increase in mast cell 
proteinases in Min adenomas and have shown that mucosal mast cells function in a 
protective, anti-tumor role in the intestine.  Although I was unable to identify the 
molecular mediators responsible for this protective effect, data suggests that it may be 
mediated through the recruitment of eosinophils.  Taken together, these results suggest 
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that inflammatory mediators function in both pro- and anti-tumorigenic capacities during 
early intestinal tumorigenesis, a concept that will be further explored in this chapter. 
 
Microarray Expression Analysis of MMPs in Intestinal Adenomas 
Previously, using in situ  hybridization, we generated an expression profile of the 
MMPs expressed by intestinal adenomas of Min mice, which suggested 1) that these 
tumors are heterogeneous in their expression of MMPs, and 2) that genetic ablation of 
MMP-7 may be functionally compensated for by increased expression of MMP-2 
(Wilson et al., 1997).  Since our initial screen, several additional MMP family members 
have been identified. Many of these genes are extremely restricted in their expression 
pattern, and in some cases are only produced by specific cell lineages.  Further, these 
initial experiments used in situ hybridization, a time consuming technique that assays 
each gene of interest independently, making analysis of large families of genes expensive 
in terms of both labor and materials.  To gain a more comprehensive characterization the 
MMPs expressed by these tumors, I utilized microarray analysis, which enables the 
analysis of thousands of genes simultaneously and allowed me to easily examine 
expression levels of MMPs and other types of proteinases in intestinal tumorigenesis.   
Affymetrix microarray experiments produce two different, but related types of 
results that are commonly referred to as absolute and relative analyses.  Absolute analysis 
generates a call of whether a gene is present or absent based upon a proprietary algorithm 
that compares hybridization of target sequence to “Perfect Match” and “Mismatch” 
oligonucleotide probes (Affymetrix, 2004).  This type of analysis is most useful for 
comparing large sets of samples, but is prone to false negatives when there is high 
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background such as the case when examining genes with high sequence homology or 
degraded RNA.  In contrast, relative analysis compares the intensity of hybridization 
between samples.  Because transcriptional regulation of many genes functionally results 
in a gradient of expression rather than simple all-or-nothing binary state, this approach 
allows more subtle examination of gene expression (Biggar and Crabtree, 2001).  Further, 
biological samples frequently contain numerous cell types, and while a given gene may 
be regulated in a binary fashion in any given cell, in the larger context of a tissue or organ 
the transcriptional contribution of each cell type typically resembles more of a graded 
response if the percent composition of cell lineages varies between samples. 
Using a custom Affymetrix microarray containing probes for all currently known 
human and murine proteinases, inhibitors, and interacting proteins; I have generated a 
comprehensive profile of the expression pattern of proteinases that are present in normal 
murine small intestine and intestinal adenomas of the Min model system.  Absolute 
analysis of isolated normal small intestine and Min adenomas confirmed our previously 
reported findings (Wilson et al., 1997), and additionally identified four additional MMP 
family members that had not previously been reported to be expressed by Min adenomas.  
Furthermore, relative comparison between these two tissues revealed three MMPs and 
several other proteinase genes that were significantly more abundant in intestinal 
adenomas than normal tissue.  These findings provide additional targets for further study 
of the development and progression of intestinal neoplasia, and provide experimental 
evidence that lead to our experiments examining other MMP family members and the 
potential role of mast cell proteinases described in Chapters III and IV.     
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I have demonstrated that transcripts encoding MMPs-10, -13, and -14 are 
significantly more abundant in Min adenomas than normal intestinal tissue as determined 
by relative analysis, and that MMP-15, which is not detected in normal intestine, is 
present in adenomas as determined by absolute analysis.  Unfortunately, I was unable to 
test the effect of genetic ablation of these MMPs.  Mice lacking MMP-10 and -13 have 
been developed (Parks, 2004; Stickens et al., 2004), but were produced on different 
genetic backgrounds than the C57Bl/6 background that is optimal for Min studies.  These 
MMP-deficient mice would need to be backcrossed in order to make uniform 
comparisons within our studies.  This process has been started but was not possible to 
finish before the completion of my studies.   
Several tumor models have detected an increase in the expression of MMP-13 that 
correlates with advanced progression (Wagenaar-Miller et al., 2004), and is frequently 
expressed by transformed epithelial cells (Blavier et al., 2006; Rath et al., 2006) and 
chronic, but not acute wounds (Vaalamo et al., 1997).   Further, genetic ablation of 
MMP-13 has been shown to limit tissue damage in a model of hepatic injury (Uchinami 
et al., 2006), and targeted inhibition by of MMP-13 at the RNA level potently inhibits 
tumor growth (Ala-aho et al., 2004).  Taken together, these data suggest a role for pro-
tumorigenic role for MMP-13 in tumor development, which suggests that had I 
completed these studies that MMP-13 deficient Min mice would develop fewer tumors 
than littermate controls. 
MMP-10 is poorly understood in the context of tumor development, though has 
been shown to be expressed by migrating enterocytes that border intestinal ulcerations, 
suggesting a role in cell motility (Salmela et al., 2004; Vaalamo et al., 1998).  
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Additionally, MMP-10 has been shown to confer resistance to p53 induced apoptosis 
(Meyer et al., 2005).  MMP-10 and MMP-3 are highly homologous enzymes (Massova et 
al., 1998), and because of the role of MMP-3 as a mediator of initiation, I hypothesize 
that ablation of MMP-10 would result in decreased tumor multiplicity in the Min model.  
However, due to the role of MMP-10 in migration, a more significant role may be 
revealed by using a model capable of metastasis. 
MMP-14 deficient animals exhibit a number of severe developmental 
abnormalities and die prematurely making them unsuitable for use in a Min study 
(Holmbeck et al., 1999).  To date, despite several attempts, MMP-15 deficient animals 
have not been successfully developed (Seiki, 2004).  We have however examined the 
contribution of four different stromal MMPs to the development of intestinal adenomas in 
the Min model system- MMP-2, -9, -12 and -19.   
   
MMP-2 Does Not Contribute to Early Tumor Development in the Min Model 
I had predicted that ablation of MMP-2 would reduce tumor multiplicity in the 
Min model.  Though not detected as differentially expressed in our microarray screen, 
MMP-2 is expressed by stromal cells in a large percentage of Min intestinal adenomas 
(Wilson et al., 1997).  Additionally, while MMP-7 ablation has been shown to reduce 
tumor multiplicity in Min mice, of the tumors that do form, all of these tumors express 
MMP-2 suggesting that in the absence of MMP-7 that MMP-2 may function in a 
compensatory role in promoting tumorigenesis (Wilson et al., 1997).  MMP-2 has been 
shown to regulate the activity and activation of other MMPs (MMP-1, -2, -13), acts upon 
a wide spectrum of substrates resulting in cleavage products with pro-inflammatory (pro-
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TNFα, pro-IL-1β) and mitogenic (IGFBP-3, IGFBP-5) effects (Cauwe et al., 2007), and 
has been shown to contribute to tumor growth in an experimental animal model of 
pancreatic tumorigenesis (Bergers et al., 2000), thus making MMP-2 an attractive target 
for further investigation. 
I have demonstrated that genetic ablation of MMP-2 does not affect tumor 
multiplicity or size in the Min model, a finding that is in agreement with previous 
unpublished studies (Wagenaar-Miller, 2002).  However, previous studies using mice 
deficient for MMP-2 in other tumor model systems, have focused on later stage disease 
and, in particular, the processes of angiogenesis and metastasis (Bergers et al., 2000).  
Angiogenesis is thought to be required once tumors achieve sufficient diameter (Naumov 
et al., 2006).  In the Min model, while adenomas may be as large as 5mm across, the 
majority of tumors morphologically are sessile, therefore flat, and thus may not require 
extensive angiogenesis.  Further, tumors in the Min model only rarely progress to 
invasive adenocarcinoma and never metastasize, so any contribution of MMP-2 to 
metastatic spread would not be relevant in this system.  Nevertheless, because of the 
overlapping substrate specificity of proteinases, there remains the possibility that in the 
absence MMP-2 other enzymes are able to functionally compensate in performing roles 
that ultimately result in tumorigenesis. 
Because of this compensatory possibility, and previous data that suggested that 
MMP-7 and -2 are compensatory in the Min model, I investigated tumorigenesis in 
MMP-2; MMP-7 double deficient Min mice.  I had anticipated that ablation of both 
MMP-2 and MMP-7 would further reduce tumor multiplicity, compared to MMP-7 null 
controls.  However, while MMP-2/MMP-7 double deficient mice developed slightly 
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fewer tumors than MMP-7 deficient littermates, this difference was not significant.  To 
examine the possibility that ablation of specific MMPs induces compensation by other 
MMP family members, we used microarray and real-time PCR analysis to compare the 
expression profile of tumors from wild type Min mice, Min mice with MMP-7 
genetically ablated, and MMP-2/MMP-7 double knockout Min mice.  Surprisingly, in 
contrast to previous experiments, tumors are largely homogeneous in their expression of 
MMPs across all genotypes examined, and the only statistically significant difference 
detected between samples was the absence of MMP-7 and MMP-2 from animals with 
those MMPs genetically ablated.  However, the absence of compensatory transcription of 
other MMP family members may be partially due to methodological limitations of 
microarray analysis, which emphasizes large differences in transcript abundance of 
genes.  Further, in order to ensure that we recovered sufficient RNA to analyze; our 
initial microarray experiments were performed on pooled tumor tissue samples, rather 
than individual tumors, which homogenizes the sample pool thus making low frequency 
transcripts appear to be more common.  However, follow up experiments performed with 
RNA isolated from individual tumors did not display variability, either.  Taken together, 
these findings suggest that MMP-2 does not contribute to early tumorigenesis in the Min 
mouse model, and that transcriptional compensation by other MMP family members does 
not occur in this model system. 
 
MMP-12 Does Not Contribute to Early Tumor Development in the Min Model System 
To investigate the role of MMP-12 in the development of intestinal neoplasia, we 
developed Min mice lacking MMP-12.  We had expected that mice lacking MMP-12 
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would develop more tumors than littermate controls, and that these tumors would 
progress to a more advanced state for a number of reasons.  MMP-12 has been shown to 
be produced by tumor epithelial cells, though as its trivial name macrophage elastase 
suggests, is primarily produced by macrophages (Lavigne and Eppihimer, 2005).  High 
levels of macrophage derived MMP-12 is commonly associated with an improved 
prognosis in colorectal tumors (Asano et al., 2007; Zucker and Vacirca, 2004).  
Additionally, a recent study by Tan, et al. found that low densities of tumor associated 
macrophages (TAMs) correlate with increased depth of invasion; and that patients with a  
high TAM had fewer lymph node metastasis and an higher 5-year survival rate than those 
whose tumors had a low density of TAMs (Tan et al., 2005).  Further, TAM have been 
associated with increased levels of apoptotic tumor cells in colorectal cancer (Higgins et 
al., 1996), and have been shown to be capable of directly stimulating tumor cell apoptosis 
(Cui et al., 1994).     
Previous work in our lab using Lewis lung carcinoma cells demonstrated that 
animals deficient for MMP-12 developed a similar number of tumors as did wild-type 
littermates, but that animals lacking MMP-12 developed large tumors more frequently 
(Acuff et al., 2006).  These studies have correlated host MMP-12 expression with an 
angiostatic host response, and implicate MMP-12 as an anti-angiogenic mediator, perhaps 
through the degradation of plasminogen to generate angiostatin (Acuff et al., 2006; 
Houghton et al., 2006; Shapiro, 1999).  Because of these reasons, I analyzed the tumor 
multiplicity and the distribution of tumor diameter in MMP-12 deficient Min mice.  
When compared to littermate control mice, MMP-12 developed a similar number of 
tumors, and tumors from both groups were similar in size.  Attempts to visualize 
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angiogenic vasculature were unsuccessful, though given the small size of the tumors, 
angiogenesis is unlikely to be required for tumor growth, a hypothesis supported by the 
literature (Alferez et al., 2008).  That genetic ablation of MMP-12 did not affect tumor 
multiplicity or size in Min mice, indicates that host derived MMP-12 is not a critical 
mediator in the development of the early stage intestinal tumors that develop in this 
model organism.  However, the lack of an observable effect upon MMP-12 ablation may 
be due to the early nature of the tumors of the Min model, and only observable by using a 
model system that develops more advanced tumors.  One such model that could be used 
to assess the role of MMP-12 in later stage tumors is the Smad-3 deficient mouse.  Unlike 
the Min model mice with Smad-3 genetically ablated develop highly aggressive tumors 
of the large bowel that are much larger in size, frequently invade through the bowel wall, 
and metastasize locally to regional lymph nodes (Zhu et al., 1998).   Based upon previous 
literature indicating a protective role for MMP-12, and data indicating that this protective 
effect is due to a decrease of anti-angiogenic factors, I predict that had I used a model 
involving later stage tumors that involve angiogenesis, that ablation of MMP-12 would 
result in increased tumor size.   
 
MMP-19 Does Not Contribute to Early Tumor Development in the Min Model System 
I had expected that ablation of MMP-19 in the Min model would accelerate tumor 
development, and that animals lacking this enzyme would develop more tumors, that 
these tumors would be larger, and potentially metastatic.  Expression analysis has 
demonstrated that MMP-19 is produced by activated peripheral blood mononuclear cells, 
TH1 lymphocytes (Sedlacek et al., 1998), and throughout the intestine in both enterocytes 
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and occasional stromal fibroblasts and macrophages (Mueller et al., 2000).  In contrast to 
most other MMPs, epithelial expression of MMP-19 is decreased in transformed cells 
(Bister et al., 2004), and lost during malignant progression (Impola et al., 2005).   
MMP-19 was only marginally detected in normal murine intestine by microarray 
analysis, and weakly in some pooled samples of intestinal polyps.  However, this 
detection pattern was similar to that of MMP-3, which was previously detected in 
approximately 50% of intestinal adenomas by in situ hybridization, and may reflect a 
large degree of heterogeneity within polyp pools.  In a previous study of skin 
carcinogenesis that used MMP-19 deficient animals, it was shown that the depth of tumor 
invasion is deeper and that angiogenesis occurs earlier in MMP-19 deficient animals, 
suggesting a protective role for MMP-19 (Jost et al., 2006).   
To examine the effects of MMP-19 on early tumorigenesis, MMP-19 deficient 
mice were crossed into the Min model.  However, ablation of MMP-19 did not affect 
tumor multiplicity or size, and no evidence of metastatic spread was observed.  Thus, 
while MMP-19 may affect later stages of tumor development, it does not influence early 
stage tumorigenesis, at least in the Min model. 
 
Leukocyte Derived MMP-9 Contributes to Intestinal Tumorigenesis 
We had expected that Min mice lacking MMP-9 would develop fewer tumors 
than littermates, but those tumors that did develop to be of a more advanced phenotype.  
This dichotomy has previously been observed in studies that used a mouse model of skin 
tumorigenesis.  Animals that lacked MMP-9 developed fewer tumors than wild-type 
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littermates, but those tumors that did develop were more aggressive and of a higher grade 
(Coussens et al., 2000).   
Using absolute microarray analysis, we found that transcripts encoding MMP-9 
were absent from normal intestinal tissue, but were readily detected in all tumor samples 
analyzed.  In the context of a tumor, MMP-9 (gelatinase B) is produced by a wide variety 
of stromal cells including neutrophils, mast cells, macrophages, fibroblasts, and 
epithelium (Noel et al., 2008).  Further, MMP-9 expression is dramatically augmented in 
colorectal tumors, and tends to increase as the disease progresses (Islekel et al., 2007).   
When mice with MMP-9 genetically ablated were bred into the Min model, 
animals that lacked MMP-9 developed significantly fewer tumors than did littermate 
controls, suggesting that MMP-9 functions in a pro-tumorigenic role.  However, there 
was no difference in tumor size, nor any evidence of local or distant metastatic spread.  
Immunofluorescent staining revealed that neutrophils are the major source of 
intratumoral MMP-9.  A single MMP-9 positive macrophage was observed, though this 
cell localized to the tumor periphery. 
A well known role for MMP-9 is as a master regulator for angiogenesis.  In our 
model, MMP-9 co-localized with neutrophils, a finding consistent with previous findings 
that MMP-9 is stored in the tertiary granules of neutrophils (Opdenakker et al., 2001).  
Neutrophils have been implicated as a key regulator of the initial angiogenic switch 
(Nozawa et al., 2006) by virtue of their granule contents which are unique in that they 
contain TIMP-1 free MMP-9 (Ardi et al., 2007).  Despite several attempts to detect 
angiogenesis by immunohistochemistry for CD-31, we were unable to reliably 
demonstrate a difference in angiogenic vasculature between samples.  Additionally, when 
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total vasculature was visualized using von Willebrand Factor as a marker, no apparent 
difference in vascularization was detected between tumors from MMP-9 deficient 
animals and wild-type controls.  While an angiogenesis mechanism would explain a 
difference in tumor size, I didn’t actually observe any such dissimilarity between wild-
type and MMP-9 null Min mice.  Thus, as previously discussed, the Min model is an 
early model of tumor development, and because adenomas that develop in the Min model 
are typically of flat morphology, extensive angiogenesis may not be required for tumor 
survival.  Hence, the pro-tumorigenic effect of MMP-9 is likely to be due to something 
other than a pro-angiogenic factor. 
The effect observed here suggests a role for MMP-9 early in the development of 
neoplastic lesions.  One potential way that MMP-9 could impact early tumor 
development is through the generation of reactive oxygen species.  Such a pathway has 
been particularly well described for MMP-3, which incidentally can also act as an 
activator of pro-MMP-9 (Inuzuka et al., 2000).  MMP-3 expression induces an 
alternatively spliced form of the small GTPase rac1 known as rac1b.  This variant 
induces an increase in intracellular ROS, elevated levels of the transcription factor Snail, 
and ultimately genomic instability, though the initial cleavage product leading to this 
change has not yet been identified (Radisky et al., 2005).  Importantly, this effect has also 
been observed for MMP-9, which has been shown to be capable of substituting for MMP-
3 in this same pathway (Radisky et al., 2005).  Further, rac1b has been shown to 
potentiate the Wnt pathway, thus enhance transcription of MMP genes (Esufali et al., 
2007) and potentially setting up a run-away feedback loop. 
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Further, MMP-9 activity could be processing cytokines, a mechanism that has 
been shown to be a major regulator of neutrophil activity.  For example, MMP-9 
mediated cleavage of full length IL-8 (1-77) to a truncated form (7-77) enhances IL-8 
activity by more than tenfold (Van den Steen et al., 2000).  This enhanced activity 
stimulates neutrophils via a positive feedback loop resulting in increased IL-8 binding, 
migration, production of MMP-9 (Opdenakker et al., 2001) and ROS (Guichard et al., 
2005), and ultimately degranulation (Van den Steen et al., 2000).  Thus, it is possible that 
MMP-9 mediated differences in cytokine signaling are involved as upstream mediators of 
rac1b expression. 
Another possibility is that MMP-9 is promoting tumorigenesis through the 
processing of growth factors, either by direct cleavage, or indirectly via the activation of 
other MMPs as previously discussed (Imai et al., 1997; Whitelock et al., 1996).  
Specifically, an MMP-9 dependent effect has been observed in the proliferation and 
morphogenesis of mammary endothelial cells.  In vitro stimulation of mammary 
epithelial cells with TNF-α induces cell proliferation and branching morphogenesis, an 
effect that is blocked with MMP-9 specific inhibitor (Lee et al., 2000).  However, such an 
effect need not necessarily be due to direct activation by MMP-9.  Specifically, MMP-9 
has been shown to activate other MMPs, including MMP-2 which has been shown to 
liberate bound IGF from binding proteins (Thrailkill et al., 1995). 
Alternatively, the effect may be the result of MMP-9 influencing neutrophil 
behavior.  MMP-9 activity has been shown to produce factors that regulate cell 
proliferation, migration, and apoptosis.  Furthermore, it has been demonstrated that 
neutrophils themselves metabolize carcinogens to reactive oxygen and nitrogen species 
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that damage adjacent cells (Josephy and Coomber, 1998).  Defects in neutrophil 
migration associated with MMP-9 deficiency have been reported in some (Khandoga et 
al., 2006), but not all (Felkel et al., 2001) model systems.  In our samples, that there was 
no apparent difference between the number of neutrophils in Min tumors of wild-type 
and MMP-9 null mice suggests that MMP-9 is not essential for neutrophil recruitment or 
migration to tumors in the gastrointestinal tract. 
In conclusion, data presented here present pro-tumorigenic role for inflammatory 
cells, in particular, neutrophils, though the molecular mechanisms responsible for this 
effect are as of yet unknown. 
 
Mast Cells Function in an Anti-Tumor Capacity 
 I assayed intestinal tumors using a novel Affymetrix microarray to identify 
dysregulated proteinases that could potentially contribute to the development of tumors.  
Interestingly, an unexpected finding of this screen was the detection of several mast cell 
derived proteinases that were more abundantly expressed in tumors than normal intestinal 
tissue.  Histochemical staining demonstrated that mast cells are more abundant in tumor 
than normal intestinal tissue, and because of these finding, I further explored the role of 
mast cells in intestinal tumorigenesis.  I have demonstrated that mast cell deficient 
animals developed more abundant and larger benign tumors than mast cell competent 
littermates.  Furthermore, tumors isolated from mast cell deficient mice had diminished 
numbers of apoptotic nuclei and fewer intratumoral eosinophils when compared to wild 
type littermates, though other leukocyte populations were unchanged between groups.      
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The prognostic significance of mast cell infiltration into tumors remains unclear 
with studies suggesting that high levels of mast cell infiltration is both a positive 
(Hedstrom et al., 2007; Nielsen et al., 1999; Rajput et al., 2007; Tan et al., 2005) and a 
negative (Gulubova and Vlaykova, 2007) prognosis in the setting of colorectal and other 
cancers.  In the studies reporting a positive prognosis, subjects were grouped into cohorts 
of high and low mast cell density and subjects with higher mast cell densities correlated 
with increased survival and a reduced risk of recurrence as well as decreased incidence of 
local and distant metastasis.  However, there remains a paucity of in vivo experimental 
tumorigenesis studies to determine the mechanisms by which mast cells exert this 
protective effect. 
My findings are contrary to a report of a pro-tumorigenic effect of mast cells in 
intestinal tumorigenesis induced by the carcinogen 1-2-dimethylhydrazine (DMH) 
(Wedemeyer and Galli, 2005).  However, there are significant differences between the 
models used in my study as compared to the study by Wedemeyer et al.  One key 
difference is the stage of the tumors examined.  DMH treatment results in malignant 
carcinomas of the colon, whereas the Min model produces benign adenomas that do not 
metastasize.  A protective effect of the immune/inflammatory system is often observed in 
early-stage tumorigenesis, whereas at later stages inflammatory mediators can promote 
tumor progression (Coussens and Werb, 2002).  In a study by Gulubova et al., a high 
density of mast cells in association with angiogenic “hot spots” was found to correlate 
with decreased survival and a poor prognosis (Gulubova and Vlaykova, 2007).  Coussens 
et al. reported that an increase in mast cells resulted in enhanced angiogenesis in a model 
of squamous epithelial carcinogenesis (Coussens et al., 1999).  However, it should be 
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emphasized that the pro-angiogenic role for mast cells reported by this group was 
observed using connective tissue mast cells, which are known to express a different 
cohort of granular proteins than the mucosal mast cells found throughout the gut 
(Bradding et al., 1995; Caughey, 2007). 
A second important difference between my study and data previously reported by 
Wedemeyer et al. (Wedemeyer and Galli, 2005), is the mechanism of tumor initiation.  
The Min mouse is the result of a single mutation at base pair 850 in the gene APC 
(Adenomatous polyposis coli) which results in a truncated protein (Miyaki et al., 1994; Su 
et al., 1992).   Mutations in the tumor suppressor gene APC are an early event in 
adenoma development (Fearon and Vogelstein, 1990), and are found in 30-70% of 
spontaneous adenomas (Ichii et al., 1993).  In contrast, chemically-induced tumors are a 
result of random mutations to known oncogenes and tumor suppressor genes.  For 
instance, tumors induced by DMH or its metabolite AOM (azoxymethane) lead to 
frequent mutations in β-catenin (Takahashi et al., 2000)  and to a lesser extent K-ras 
(Takahashi and Wakabayashi, 2004), both of which are rarely mutated in Min adenomas 
(Shoemaker et al., 1997b; Suzui et al., 2002).  The consequence of mast cell interactions 
with tumor cells may be dependent on the underlying genetic alterations in the tumor.  
Lastly, in my study, the mice that were used were of a pure C57Bl/6j background, 
whereas the previous report used a WB-C57Bl/6j F1 hybrid.  Strain differences have been 
reported to affect tumorigenesis and progression in both the Min model and DMH/AOM 
induced carcinogenesis through the presence of modifier loci (Diwan and Blackman, 
1980; Moser et al., 2001; Shoemaker et al., 1998).  There also remains the possibility that 
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differences exist in the intestinal microenvironment between the two strains, and that 
these are responsible for the discrepancy. 
My data suggest a model whereby mast cells function in a protective role by 
promoting apoptosis of tumor cells.  Mast cells have been shown to indirectly induce 
apoptosis via degradation of extracellular matrix components by mast cell produced 
chymase and granzyme B leading to epithelial cell anoikis (Ebihara et al., 2005; Pardo et 
al., 2007).  In addition, mast cells have been shown to directly mediate tumor cell 
apoptosis via secretion of soluble factors such as TNF (Latti et al., 2003) or by 
production of reactive peroxides (Henderson et al., 1981).  While capable of direct 
cytotoxicity, mast cells have been shown to enhance the cytotoxicity of other 
granulocytes, and in particular, eosinophils (Capron et al., 1978).  
There are multiple levels at which eosinophils are regulated:  generation in bone 
marrow, emigration from bone marrow, recruitment to tissue, activation and 
degranulation.  Evidence exists for mast cell produced factors having the ability to 
regulate all of these steps.  For example, mast cell secreted IL-5 and stem cell factor 
(SCF) have been shown to control differentiation of hematopoetic precursor cells into 
eosinophils (Metcalf et al., 2002; Oskeritzian et al., 1996).  Eosinophil migration, 
particularly in the intestine, is largely mediated by the chemokine Eotaxin-1, an activity 
that is impaired in mast cell deficient mice (Harris et al., 1997).  Additionally mast cell 
produced chymase has been shown to induce eosinophil migration in vivo (He and Walls, 
1998).  Activation and degranulation of mature eosinophils has been shown to be 
dependent on mast cell produced SCF and leukotriene C4 (Oliveira et al., 2002).  Once 
activated, eosinophils are capable of producing several soluble factors that have been 
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shown to induce apoptosis of tumor cells such as eosinophil peroxidase (EPO), 
eosinophil cationic protein (ECP), major basic protein (MBP), and granzyme B (Costain 
et al., 2001).  Hence, there are multiple ways in which mucosal mast cell deficiency can 
impact eosinophil biology.   
Based on the correlation between presence of enhanced populations of both 
mucosal mast cells and eosinophils in the intestine of Min mice, my data suggests a 
model whereby mast cells are protective in the intestine through both direct effects on 
tumor cell apoptosis and/or indirectly through the recruitment and activation of 
eosinophils.  This model is supported by reports of mast cell and eosinophil function in 
immunosurveillance and by studies that correlate high mast cell and eosinophil infiltrates 
with a good prognosis in colorectal cancer (Nagtegaal et al., 2001; Pretlow et al., 1984).    
My studies provide experimental evidence to support the epidemiological observation of 
a protective effect of mast cells on colorectal tumorigenesis.  Conversely, in comparison 
to the pro-tumorigenic effect observed for neutrophils, I have demonstrated an anti-
tumorigenic role for mast cells. 
 
Conclusions and Future Directions 
 
 The work in this thesis began as a study of the range of proteolytic enzymes 
expressed during the development of intestinal tumorigenesis.  I then began to examine 
potential functional roles using a genetic ablation approach.  During the course of these 
studies I have discovered that the cellular sources of many of the proteinases relevant to 
tumor development are inflammatory cells.  Chronic inflammation has long been 
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associated with the development and progression of neoplasia, and taken together, these 
experiments further refine the role of MMPs and inflammation in early intestinal 
tumorigenesis.  For example, several studies have shown that patients with long-term 
inflammatory bowel disease have an increased incidence of colorectal neoplasia (Xie and 
Itzkowitz, 2008).  However, the molecular mediators linking inflammation to the 
development of neoplasia are still obscure. 
We have demonstrated that MMP-9 promotes tumor formation, and that 
neutrophils are the major source of MMP-9 in these tumors, although the mechanism 
behind this is unclear.  While neutrophils are the primary intratumoral source of MMP-9, 
we cannot exclude the possibility that another cell type produces this enzyme much 
earlier in tumor development, and that initial expression is ultimately what initiates 
tumorigenesis.   
One such pathway that has been previously implicated in MMP-9 mediated 
tumorigenesis is through the induction of ROS.  Reactive oxygen radicals have long been 
implicated in the development and progression of tumors and have been demonstrated to 
stimulate tumor development via several mechanisms including by the promotion of 
genomic instability, cellular proliferation, angiogenesis, motility, and the influx of 
inflammatory cells.  However, there exists a paucity of in vivo data using broad, multi-
stage models to support the role of ROS in tumor development.  Recently however, 
genetic and pharmacologic agents have been developed that inhibit ROS production and 
activity (Storz, 2005), and application of these models in the context of tumor 
development could refine the role of ROS in tumorigenesis. 
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While ROS activity may ultimately be responsible for tumor development, the 
upstream mediators that ultimately trigger this pathway remain obscure.  The obvious 
approach to identify these candidates is through proteomic screening.  However, previous 
attempts to identify substrates for MMP-7 using whole tumor extract at various stages 
produced inconclusive results.  However, unlike MMP-7, MMP-9 expression is 
ultimately a product of bone marrow derived cells that can much more easily be 
manipulated, perhaps even to allow comparisons from within the same mouse. 
Furthermore, these studies have clarified the spectrum of MMPs known to affect 
tumorigenesis in the Min model.  We have now shown that MMP-7 and MMP-9 both 
promote tumorigenesis, while MMPs-2, -12, and -19 do not affect tumor multiplicity or 
size.  While we did not find evidence of compensatory transcriptional upregulation 
between MMP family members, there exists the possibility that despite similar transcript 
copy number enhanced mRNA stability or translation of more protein is present in tumor 
compared to normal tissue.  Further, there may be functional compensation across MMP 
or even other proteinase family members that is simply not measurable by assaying 
transcript abundance.  In retrospect, that MMP-2;MMP-7 double deficient mice behaved 
similarly to MMP-7 deficient mutants is not surprising given that MMP-2 ablation did 
not affect tumor multiplicity.  However, given that both MMP-7 and MMP-9 have been 
shown to affect tumorigenesis alone, it would be worth assessing them both in 
combination. 
In this thesis, I have provided experimental evidence showing that inflammatory 
cell populations function in both pro- and anti-tumorigenic fashions.  I propose that as 
illustrated in Figure 24, shifts in the balance between these two diametrically opposed  
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 Figure 24:  The balance between anti- (blue) and pro-tumorigenic (red) effects of 
inflammation exists as a continuum within the intestine.  Neutrophil-derived MMP9 
functions in a pro-tumorigenic fashion, and thus genetic ablation results in decreased 
tumor formation.  Conversely, mast cell deficiency impairs normal anti-tumorigenic 
effects resulting in enhanced tumor formation. 
 
 
 
functions ultimately determine the nascent tumor fate.  Testing this hypothesis requires 
an appropriate mouse model system that allows the examination of various leukocyte 
populations throughout various stages of tumor development.  Ideally, testing the role of 
neutrophil derived MMP-9 would be achieved using a mouse that lacks neutrophils.  
While there do exist mutant mice that lack mast cells, eosinophils, lymphocytes and to a 
degree macrophages, there are currently no known lines of neutrophil deficient mice.  
While it is possible to largely eliminate neutrophils by the treating mice with an anti-
neutrophil depleting antibody, this effect is short lived, requires repeated treatments, and 
given our current understanding of tumor development in the Min mouse, would require 
that developing mice be treated in utero.  Nevertheless, supposing these technical 
challenges could be overcome, if the major source of MMP-9 is neutrophils, then I would 
expect that Min mice lacking neutrophils and MMP-9 knockout Min mice would develop 
a similar number of tumors.   
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A problem with this approach is that while it does allow the direct testing of 
neutrophils, it supposes that neutrophils are strictly functioning as pro-tumorigenic 
through the release of MMP-9.  It is possible that while neutrophil derived MMP-9 may 
promote tumorigenesis, other neutrophil derived factors function in an anti-tumor 
capacity, and that a relatively crude approach of simply removing all neutrophils could 
result in increased tumor burden.  A cleaner system would be to develop a tissue specific, 
or even cleaner, a cell specific knock-out.  A genetic mutation resulting in the lack of 
neutrophil secondary granules has been identified in mice, however, to date the genetic 
elements responsible for tertiary granules, the granules that contain MMP-9, have not 
been identified (Lekstrom-Himes et al., 1999).  However, if such a gene were to be 
identified, it could be used to breed mice specifically lacking neutrophil derived MMP-9 
while retaining other neutrophil activity for examination in the Min system.   
Conversely, I have shown that ablation of mast cells results in enhanced tumor 
formation, presumably through an eosinophil effected mechanism, though the molecular 
signals behind this modulation are unknown.  The most obvious next step is to investigate 
the effect of eosinophil ablation in our model system.  Two eosinophil deficient mouse 
lines have been described to date, IL-5/CCL11–/– and dblGATA that could be used to 
examine the role of eosinophils in this system.  Assuming that mast cells activity is 
simply to modulate eosinophil activity, I would expect that eosinophil deficient Min mice 
would phenocopy Min-Sash mice.  However, a more likely outcome is that eosinophil 
deficient Min mice would develop more tumors than eosinophil competent littermates, 
but less than Min-Sash mice, thus indicating that mast cells exert their anti-tumor affect 
through multiple cell types.   
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Mast cells were initially identified in our model due to an increase in the 
abundance of several mast cell produced proteases.  It is likely that different sub-cohorts 
of mucosal mast cells express different combinations of mast cell proteinases (Friend et 
al., 1998).  While I have broadly examined the effect of ablating mast cell proteinases by 
removing mast cells entirely from the system, the role of the individual proteinases has 
not been assessed.  Knockout mice lacking every known mast cell proteinase individually 
have been developed.  Unpublished data has demonstrated that mcpt-4 deficient mice 
develop dramatically smaller tumors in a fibrosarcoma model, a change that is likely due 
to a reduction of angiogenesis in the knockout animals (Stevens, 2008).  However, the 
major mast cell proteinases that were more abundant in our tumors were mcpt-2 and 
mcpt-5, two chymases that have not to date been closely studied in the context of tumor 
development.  However, chymases have been implicated in the induction of apoptosis 
(Heikkila et al., 2008), and since we do see a reduction in apoptosis upon mast cell 
elimination, it is reasonable to hypothesize that genetic ablation of these proteinases 
would result in a reduction in apoptosis, though because of the overlapping substrate 
specificity of murine mast cell proteinases (Stevens, 2008), a combination of multiple 
mast cell proteinases may have to be ablated to have an effect. 
Alternatively, rather than focusing on specific cell lineages, it may be more 
beneficial to explore the role of broadly expressed inflammatory molecules in the 
development of intestinal tumors.  For example, genetic ablation of MyD88, a toll-like 
receptor (TLR) adaptor molecule expressed in several leukocyte lineages, has been 
shown to dramatically inhibit tumor development and progression in genetic and 
carcinogen induced models of colorectal cancer (Rakoff-Nahoum and Medzhitov, 2007), 
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suggesting that it may be more beneficial to examine specific pro-inflammatory pathways 
rather than specific cell populations. 
In conclusion, I have presented evidence that components of the innate immune 
system function in both pro- and anti-tumor capacities early during tumor development.  
Further characterization of the molecular mechanisms responsible for these effects could 
lead to novel therapeutic strategies in the treatment and prevention of cancer. 
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